Registered number: 08239097 Charty number: 1149638 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarantee) TRUSTEES. REPORT AND FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 •ADcr#iKE6" 2511)912024 c(￿PANIEs H¢XJSE THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Limited by Guarantee) CONTENTS Page Reference and Administrative Detaik of tho Companyp its Trustees and Advisers Trustees. Report 2-17 Tru8tee8' Responsibiliti•s Stst•ment 18 Independent Auditors. Report on the Flnan¢lal Statements 19-22 Statement of Flnanclal Activities 23 Balance Sheet 24 Statement of Cash Flows 25 Notes to th• Financial Stst•m•nts 26-44 ThE FEDERATION OF EUROPEAN BK)CHEMICAL SOCIETIES (A Company Limlted by Guarantee REFERENCE AND ADUINISTRATNE DETAILS OF THE COMPANY. ITS TRUSTEES AND ADVISERS FOR THE YEAR ENDED 31 DECEMBER 2023 Trustees P Ladler. Congress Counsellor (appointed 1 January 2020) F Michelangeli, Treasurer (appointed 1 January 20171 F G Sajin, Chair. Educab'on and Training Committee {appoinled 1 January 2019) l Diaz Moreno. Chair. Careers of Young Scientists Committee (appointed 1 January 20181 B Vèrtessy, Chair, Advanced Courses Committee (appointed 1 January 2015, resigned 31 De￿mber 2023} M De La Rosa, Se￿1¥ry General (appointed 1 January 20131 J Dumié, Chair. Integration and Ne￿Orknng Commrtlee {apF4)inted 1 January 2017) E Fragkoulis, Chair. S¢ieno and Sw"ety Committee (appointed 1 January 20171 A Krol. VI￿ Chair, Chair, Excellence Awards aNI Fellowships Committee (appointed 1 January 2017) J Kos, Vice Chair lappointed 1 January 2021) J Buchner, Chair. Pu￿1call0nS Committee laprh)inted 1 January 2021) X D C Coumoul. Ctschair, Integrabon and Nelworking Committee (appointed 1 January 20221 C Dean, Chair, Wothng Group on Women in Sc*nce (appointed 1 January 2023) G Soveral, Chair lappointed 1 January 2023} M Maccarrone, Chair. Advanced Courses Committee (appointed 1 January 2024) Company registered number 08239097 Charlty reglstered number 1149638 RagiBt•red office 2D & 2E, Sl Andrew's House. 59 St Andrews Street. Cambridge. C82 38Z Company secretary Professor M De La Rosa Independent auditors Hill Wooldridge & Co. Limited. 107 Hindes Road. HatTth¥. Middlesex, HA1 1RU Bank•rs HS8C UK Bank PLC. Business Banking UK. 1 Com Market & Church StreeL High I1￿￿rnbe, HP112AY Investment managews J.P. Morgan Private Bank. 60 Victoria Embankmen( London, EC4Y OJP Page 1 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Llmlted by Guarantse) TRUSTEES. REPORT FOR THE YEAR ENDED 31 DECEMBER 2023 The Trustees present their annual report togelher With the audited finanoal statements of the Company for the year 1 January 2023 to 31 December 2023. The Annual Report seNes the purposes of both a Trustees, report and a directors. report under Company law. The Trustees confim Ihat the Annual Report and financial statements of the charitable company comply the current statutory requirements, the requirements ol the charitsble companys goveming document and the pn>visions of the Statement of Recommended Practice ISORPI applicable to charities preparing their accounts in accordance with the Financial Reporting Stsndard applicable in the UK and Republic of Ireland IFRS102) leffectwe 1 January 2019). Since the Company qualthes as small under sects.on 382 of the Companies Act 2006. the Strategic Report required of medium and large companies under the Companies Act 2006 IStrate9ic Report and DireGtor5' Report) Regulations 2013 has been omitted. STRUCTURE, GOVERNANCE AND MANAGEMENT Constitulion FEBS is registered as a dHnty (registered ¢hanty number 1149638), and vs a company limited ty guarantee (registered company number 08239097). The Memorandum and Arti¢les of Asso¢iation by which FEBS was governed in 2023 Can be found he￿". httpsJhMw.febs.orfv¢onlenVuploads120221081FEBS_- -memorandum and_Articles of_Assouation.pdf. OTganis•tion and m•mber4hlp FE8S was founded on 1st January 1964 and is a Federation of biochemisty and molecular biology societs'es. In 2023, its Constituent Sweltes spanned 39 countries in Europe and neighbouring regions and included 35 Member Societies and 4 Asscoate Member Societies. The Constituent &Kieties of the Federation in 2023 are given in Appendix 1. and their membership numbers in Appendix 2 {lotalling 23,822 individual members in 20231.12 societies- Ru$$ia and Belaru$- had their MeMbe￿hIP of FEBS suspended following a CtyJncil vote in 2022 and they ¢urrenty remain suspended.) FEBS is governed by a Courril coff4)osed of one delegate from each of the Constituent Societies as well as the members of the ExecutNe Committee. FEBS Council meets once a year at the annual FEBS Congress. The Council elects members of the FEBS Execulwe Committee for three-year terms {excepl the Chair and.Vice- Chair positions). as well as ordinary members of the FEBS Committees and Working Groups Idele9aled specthc areas of FEBS workl for four-year tenn5, in a secret ballot. The Vi¢e£hair of the Executive Committee, who after one year becomes Chair. is appointed by the So¢bety I￿$￿"n9 the annual Congress and Council Meeting in the previous year. Subject to the Counal. the administration of the Federation is vested in the FEBS Exe¢utNe Committee (the 'FEBS Officers'l. The Executive Committee cnnsists of the Chairperson, the Vi¢e£hairperson, the FEBS Secretary General, the FEBS Treasurer. the FEBS Congress Counsellor, and the FEBS Committee and Working Group Chairpersons. With Ihe exception of COwOPted Acting chairy￿r$OnS le.g. following resignations prior lo Council elections). FEBS offi￿lS are the FEBS charity Trustees and Company Directors responsible for the actions of FEBS. The names of the members of the Executive Committee and the names of members of other Committees and Working Groups in 2023, together dates of appointments and geographical distribution, are set out in Appendix 3. The FEBS TrusteeslDirectors are distsnguished s¢ienb"5ts and {wth the exception of the Exe¢Lrtive Committee Vice Chair and Chair, as explained above) elected by FEBS Council from nomination5 PLIt forward by FE8S Constituent Societie5. Before formal appoinlmenL newly elected TrusleeyJDirectors sign the Charity Commission's 'Declaration of eligibilty for newty appointe(l Trustees. and are referred to the Charity Commission's guidance on the role of Trustees as well as Companies House infomiation on D1￿CtorISe¢retsry roles. Page 2 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Llmlled by Guarantee) TRUSTEES. REPORT ICONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 OBJECTIVES AND ACTMTIES ObJectiv•s The objectives of FEBS are to contribute to and promote the advan¢ement of research and education for the public benefit in the $C￿nceS of biochemisty. molecular biology and ￿￿ted disuplines Ibui only in so far as such related disciplines are ancillary to the main obj'ect), by all suitsble means and in particular by.. holding and arranging congresses. training and educational coJrses on matters connected with biochemistry and ￿0￿Cular biology and related disaplines. facilitatsng and supportjng the exchange ot scientific informabon be￿eeTh bicthemists. molecular biologists and suenkn.sts working in related dwplines generalty and especialty in Europe and other countries of Constrtuent Souebes. fa¢iltsb"ng and supporhng the training of young scienb.sls in resear¢h, in the fomi of fell¢)wships", and organising the edrting and publication of suentsfic researeh and educabtsnal material in biochemisty and mole¢ular biology and related disoplines. Actfvltle8 The following paragraphs and their asswated appendus oulline activities in 2023 from the different Committees and Working Groups of FEBS. Extensive infomalion on FEBS work is also available on the FEBS website al vfjvw.febs.org and h￿hlIghts appeared in the issue of FEBS News {pdf magazine) in 2023.. https:lfvthw.febs.otynewsttebMew>m4a2inel. Stiategic Priorities 2024- 2028 FEBS future income faces a less certain fvlure due to oFen access pU￿lshI￿9. uncertainty al)oul the fvture of academic publishing models and reduced incorTE from our publishing agreewent. as well a5 due to the current difficult soci￿Con0M1c circumstances world￿de impacting on our investment returns. The￿ are p0511ive prospects including the suentific cornmunity's contribution to the pandemi¢ and opportunities to work more closely with FE8S member societies and other closely related scientific organisations to provide tenefit lo molecular tile s¢en¢es in Europe and beyond. During 2023. FEBS has undertaken a review and fomulaled ts Strateg￿ pnonties for the next five years. led by the Executive Committee and in consubtation wrth FEBS Council. The main topics identifwl during this process were.. Collaboration and synergy, Congress and events" Income and diversification". and Marketing and promotion. Followng this initial work, necessary updates to FEBS Articles and By L¥Ns wll be drafted for Counc41 approval. followed by the timeline for the implementslion phase of the pnorrties idenb'fied. As part of the consultation wth the Council. approval was given for the former working groups Careers ofyoung Scientists. Integration and the FEBS Netsvork to become committees. lo provide consistency wrth the existing named coffmittees. ScientifK publl¢ations FEBS owns four joumals for the publicatson of research papers, reviews and discussion in the molecular life sciences.. The FE8S Joumal. FEBS Letters. Molecular Oncology and FEBS Open Bio. They are published on behalf of FEBS by Wiley and aim to provide highquality peer revi&¥, fast putAicalion, and a variety of enhanced features for both authors and readers. The joumals provide rrb)st of the income to fund FEBS. othei acb"vities. The Publications Committee oversees the operats.on and devebpment of FEBS, journals and in 2023 was Under the chairmanship of Johannes Bu¢hner. Income and costs of the Jouma15 in 2023 are in the Strategic Report section of this Annua Report Al fI￿r joumals are inlemationally reco9nised to be of hwjh quality as detailed Page 3 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Llmlled by Guar•ntee) TRUSTEES. REPORT {CoP￿INUED) FOR THE YEAR ENDED 31 DECEMBER 2023 below. The four Joumals are fuNy digital and can be reached through the FEBS Press plaffo {WVhV.febspress.coml. The FEBS Press Joumals have embraced changing publishing practices and offer simple submission in any formal and a sm¢wth publutr.on process. wth peer review managed by editorial board members who are experts in the field. Thorough ethics and research integrity checks are run by our experienced editorial stsff prior lo article publication. All journals now puWish peer review reports alongside research articles. Authors of articles jected by one FEBS Press ioumal ¢an choose to have their manuxnpt aulomab"¢alty transferred to another. All joumals offer open access options: over 70% of total art￿e$ published in 2023 were open access {vs over 60% in 20221. The FEBS Joumal Iwww.febsjoumal.org) publishes hvJh-quality fulHength research papers relevant to the molecular, cellular and biochemical lrfe sciences. The journal also publishes a diverse portfolio of commissioned frontthalf content review and editorial content, induding State-of-Ihe-Art Reviews, Commentsries, Discovery-in£ontext Reviews. Strurtural Snapshots, Viewpoints, INords-of-Advice guides and interviews wlh eminent S￿entiSts {In Conversation Wrth ...) Key Metrics 2023 published in 2024.. Key Metrti 2023.. Impacl Factor 5.5 . CIteSco￿ 11.7 . Cited Half4ife 7.5 years , Median tirne from submission to first decision after peer review: 41 days. In 2023, the joumal published 365 articles in 24 issues. Authors have the opb.on of publishing their art￿le open access. FE8S Letters {www.febsletters.org). pU￿1$he5 research reports (both short Letters and fu114ength articles) thal significanty impact and advancE knowledge in the nK)lecular bioscien￿." editorial speed is a key fealure of the journal. The joumal also publishes a diverse range of Reviews (including In a Nutshell and Perspeelivesl and other front-half conlenl (Commentaries. Scientists. Forum). Key Metrics 2023 published in 2024.. Key Metrics 2023.. Impact Factor 3.0 , Crtescore 6.6 . Cited HaK-life 17.5 years , Median tirne from submi55iOll to first decision after peer review.. 27 day$. In 2023, the joumal published 231 articles in 24 issues. Authors have the opb.on of publishing their arb.ck open access. Molewlar Oncokwy {wMw.moloncol.Ofg) publishes highqmpacl research arti¢les in basic, translational and dinical cancer research. The ioumal also publishes commissioned reviews and PDliry papers discussing emerging concepts in cancer research. cancer dIagnO￿S, prevention and care. Key metrics for 2023 published in 2024.. Key metn.cs 2023. Impact Factor 5.0 , Citescore 12.6 . Ciled Half-lifr 4.7 years , Median time from submission to first dectsion after peer review. 47 day5. In 2023, the journal published 174 artides in 12 issues. The joumal is fulty open access.. FEBS Open Bio {www.febsopenbio.Ofg), publishes research articles, methods and protocols across the molecular and cellular life sciences. with the emphasis on technical and ethical quality rather than subjecttrve jud9ements of significance. Research arb.des on Education in the rrvJlecular life sciences are published free of charge. Key metrics for 2023 publishe(l in 2024.. Key Metrics 2023". Impact Factor 2.8 , Citeseore 5.1 , Cited Half-life 4.1 years , Median ts.me from submission lo first decision after peer review.. 36 days. In 2023. the journal published 177 artides in 12 issues. The joumal is fulty open xcess. The FEBS Network The 'FEBS Nefv￿rk, ￿atFOrM {1) hosts blog-type wsls offering insight. advice. news and ￿mMentarieS for molecular life suentists (under the themes Earty£areer Scientr"sl. Educator, Viewpoints and Research}, and {21 supports the development of an online community of scientists through presentation of profiles, and functionalrties such as fOl￿wing. commenting and open or private rooms. It also offers a channel for posts and a pnvate room for FEBS Constituent Sociebes, and hosts vKleos such as interyiews and recorded talks. The FEBS Ne￿ork in 2023 was overseen by the FEBS Netsnrk Committee. comprising scientists delegated from other FEBS Committees or elecled. and chaired by Prof. Xavier Coumoul. Wiley had offered collaborab.on lo develop a FEBS Ne￿Ork in the joumal Publishing Agreement 201￿2023. The cutrenl aims of the FEBS Nefv4oTk include {11 supportin9 and enhancing the key FEBS activib'es of ioumals and events, as well as other FEBS work such as education. saence & society and fellowships."12) providing an innovative offering from FEBS as a new way to support the mlecular life sciences Page 4 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Llmlted by Guarantse TRUSTEES. REPORT {CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 community.. and {31 buikling rrKJre access to scientists inte￿$te￿ in FEBS activities. FEBS F*llowships The report from the 2023 Chairnan of the Fellowships Comm￿ee. Prof. Alain Krol, provides infomialion on the range of applications recÈNed for the variou5 ￿tegOrieS of Fellowships. Following the final eall for Long-Term Fellowships in 2020 (when 77 ap￿icatiOnS were receNed}. 6 new Fellowships were awarded and were taken up frorn January 2021. the totsl in post duriThJ 2023 was 3 (Append￿ 4) and the LTF'S final year in post ts 2024. 43 eligible Short-temi Fellowships ISTFS) applutions were received in 2023 and 24 were awarded. These funds enable aelive young scienlisl$ to work for up to or three months in laboratories in another FEBS country. In 2023, 42 eligible Summer Fellowship applIcat￿nS were received and 11 were awarded to promising MasterslPhD sbJdenls to prOV￿e a laboratory exFerience. 2 Collaborative Experimental Scholarship {CDSI applications were received in 2023 and both We￿ awarded., the aim of the CDS is lo provide Pho students and young scientists from HINARI IResearch4Lifel countries wth travd and daity allowance so thal they can carry out experiments which woukj be Imp￿ble in their countrtes. FEBS Excellence Award The first call for this new program was made in June 2021. This •*ard is intended for earlyacareer scientists who have been estsblished in a salarièd ¢aparyty in a host institutson of a FEBS Constituent Society as a Principal Investigator IP1} for at least one year. The Award is endowed a É100.000 grant for 3 years to be used exciusively for purchasing consumablelequipmenL In 2023. 40 elHJible applicatsons were received and 10 were awarded. Ukrainian Short-Tenn Fellowshlps (USTS): these were intrcKlu¢ed in spring 2022 to help scients'sts in or displaced from Ukraine. They suppjrt visits to a host laboratory for up to 4 months. The de¢i5ion ft)r acceptance is given rapidly - uyjally wthin 3 weeks of apptying. 3 USTS were awarded in 2023. all of them for a 4-month period. Advanc•d Cour••s 16 courses events took place in 202317 Advanced Lecture Courses. 1 joint FEB&EMBO Lecture Course, 2 Practical Courses, 1 combined Prxtical and Lecture Course. 2 Speu81 Meetings and 3 Workshops} with Jntinued EMBO and IUBMB support FEBS Advanced Courses proV￿e research updates and teaching from scientific leaders in a partj'cular field and are particularfy valuable for early-career researchers. Interaction of participants with eXP￿ts and peers is facilitated through a variety of session fom)ats. In 2023. grants lo course organisers tolalled approximately É335,904. Furthemore. Youth Travel Fund grants (YTFI. which in 2023 total￿d Q3,288, were gNen to support partru"pab"on in Advanced Courses to 96 young members of FEBS Conslituenl Scaelies from outside the host county {81 YfFs were given in 20221. In addition. 12 IUBMB-transconts"nental YTFS supported the parb"cipats"on of students OUts￿e FEBS area. A collal)oralion conb'nued be￿een FEBS Advanced Courses Committee and FEBS Letters, which was initiated in 2019. Organisers are encouraged to parbcipate in provhling hKJh-quality material in the fonn of a Special Issue or a Virtual Issue in order to provMJe the course organizers wth the opportunity to gain broad visibilty of their work in a wel￿r*￿ted joumal. The 471h FEBS cOngr￿S The annual FE8S Congress is overseen by the FEBS Congress Counsenor {who, in 2023. was Prof. Piotr Laidlerl, jointly wth the Secretary General {who. in 2023, was Prof. Miguel A De la Rosa}. The 47th FEBS Congress, with the title Togelherin bIosc￿nce fora betterlulure, took place from 8th to 12th July 2023 in Tours, France and was hosted by the F￿nch ScKiety for Bio¢hemisty and Mole¢ular Biolcgy {SF8BM}. The Congre$$ bhl was accepted in a vole by the FEBS Council at their meeting in 2022, as an artemative location following the cancellation {for reasons ouuined in FEBS 2022 Annual Report) ofthe hxatbon of MosTh. Russia. Despite the shorter tiMeSca￿S for organising the Congress in a new Iccation of Tours, Franee, the Congress attracted 1,076 parbcipants from 65 countries and the event featured an attractive scientific program comprising Page 5 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarants•) TRUSTEES. REPORT {CONnNUEDI FOR THE YEAR ENDED 31 DECEMBER 2023 11 plenary lectures, 74 regular speakers and 6 special session speakers from 34 countries and, in addition to plenary lectures and poster sessions, there were 21 symposia topics and special sessions including FEBS Press Meet the Editors. Science in the Street for members of the public. Publication ethics and Education Committee events. 825 abstracts were acttpted, induding the invrted s￿kerS, abstr￿lS and 652 poster presentations. 60 speed talks and 27 short tslks which featuRd in the scientffic programme. FEBS continued to provide specffic addibonal funding support for Ukraine saentisls or displaced from Ukraine who were submittj'ng abstracts to the 2023 Congress {as was offered at the 2022 Congress). In addition to providing a grant for the organisation of the Cong￿5$. FEBS ¢onbnues to support the partiupation of young scientists at the event through Congress bursaries and through rts Young S¢ientists' Forum awards {usualty 100 participants. including the organiwng committee). FEBS provides support with redU￿d registration fees for FE8S members of Hinari {Resear¢h4Lifel countries in the FEBS area called the Sprinzl Scheme. Congress Management and Development and future Congresse5 The fulure FEBS Congresses and Young Saenlist Forums IYSF} wll be as follows: the 48th FEBS Congress, hosted by the Italian Society of Bioehemisty and Molecular Biology ISIB), wil tske pl* in Milan. Ilaty in 2024, preceded by the 23rd FEBS YSF" the 49th FEBS Cong￿$$, hosted by the Turkn"sh Biochemical Society. wil take place in Istanbul, T(hrkiye. in 2025, preceded by the 24th FEBS YSF.. the 50th FEBS Congress, hosted by the Netherfands Society for B￿hemISty and Mokujlar Biology. wdl take place in Maastricht. The Nelhertands in 2026. preceded by the 25th FEBS YSF. FEBS continues to take out a cancellats'on insurance pJli¢y for each Congress and, although event insurance cover has changed because of the COVID-19 pandemic. FEBS takes out this insurance policy. as an example of FEBS, responsibilittes as a charity to manage risk and effectively delrver its aims, along y￿h the ¢ontra¢ts in place with the ProfesS￿rtaI Congress Organiser {PCOI and Host Society. Young Scientists. Fowm (YSF) The Chairperson of the Careers of Young Soentists Committee. Prof. Irene Dlaz-moreno. and an organising committee of young scientists organise the YSF. The 22nd YSF took place in Tours. France 6th- 8th July 2023. 298 applications were received from 40 countries. 97 pre-and posl-docloral young scientssts from FEBS member soaeties. representing 31 FEBS member so(xty countrbes, attended the event, supported by grants from FEBS and 2 places supported by the Biochemical Society IUKI. The program consisted of an Opening Lecture and 2 Keynote Lectures, 6 YSF Career Speakers, across 2 sessions on 'Career Skills., 10 selected Oral Communication talks across 2 sessions as well as s(Kial activrties. YSF part￿1pants also attend the Congre$5, uring whieh the YSF Bridge event was hdd. This event was organised by the Chairperson and an intemational organising committee of young suents'sts. ENABLE As agreed in 2021. for the event organisation, FEBS and IUBMB work wilh the ENABLE core partner European inslitule. appointed following an open ¢all for bids and who acts as the host and take responsibility for the Symposium ea¢h year, and this agreement wns from 2022 to 2025. There will also be a Scientific Organising Committee and Local Organising Commfftee for each event. The FEBS4UBMB-ENABLE Symposium was held wi Europe in 2022 and 2023. will be held outside Europe in 2024 and be held in Europe again in 2025. Travel grant supFort will be provided to young saenb"sts. The FEBS-IUBMB-ENABLE 2023 conference. with the title'Tr en￿rgIng tha1￿nge- environmental impacts on human health,. was hosted by the University of Cok¥3ne in Germany. on 2>25 November 2023. 240 young sear¢hers participated from 32 countries wlhin and outside of the EU. The ujnference included a scientific sympjsium, workshops on personal and profes￿Onal development. outreach acb'vities for the general public and a dedicated career day and job fair. 13 SFX)nsors supported this inth'ative and their contribUt￿n allowed support to be given for a totsl of 62 travel grants. Page 6 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Llmlled by Guarantee) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 FEBS 3+ Meetings and FEBS Notional Lectures FEBS supports scientific events of rts Constituent Societies through the FEBS3+ meetings program and the FEBS National Lecture scheme, overseen by the FEBS Congress Counsellor (Prof. Piotr Laidler in 2023). The FEBS3+ meetings program provides funding for meetings organised through collaborations of at least three FEBS Constituent Societies. FEBS approved an applicats'on for the FEBS3+ meeting KXVII Biochemisty Congress 2023 hosted by the Slovak Sooety for Biochemisty and Molecular Biology and held in the High Tatras, Slovakia in ¢onjun¢tion with the sooetse$ CSBMB Iczech Republic}, MBKE (Hungary} and UBS Iukfainel. This meeting featU￿d 3 ￿enary speakers. 66 regular session lectures. 93 wsters and 227 parti¢ipants. FEBS support consists of E10.000 lo the host society for general meeting ￿ganISatIon and É10.000 to support the attendance of young scientists from the other part￿"patr"￿ societies. In 2023, FE8S supported 7 FEBS Natit>nal Le¢iures. by funding the attendance of key speakers from a different FEBS county invited by a FEBS Constituent s￿ety to their national meeb'ng through FEBS Natsonal Lecture Awards. The seven FEBS Nath)nal Lectures were awarded to national society meetings of the member societies of 8osnia and Herzegovina, Itaty, Poland. ROM￿￿, Sloven￿. Spain and Tlirkrye. Other events In the framework of promoting FEBS. ioumals and FEBS. collat#)rath)ns wrth related intemational organisations of M￿eCUlar h.fe sciences. FEBS continues to support. through sponsorship of events and travel ¢osls for distinguished speakers to delNer Wures at annual meetings of leamed soc￿￿eS of biochemistylmoleeular biologylcell bioiogy in parts of the world wrth rnpidly developing ¢ontnbLthns to molecular life $eiences research. Sciènce & Society {S&S) The Science and Society Committee athitses in the year 2023 included.. the Science and Society Special Session during the FEBS Congress in Tours, Juty 2023, was held as a Scien¢e in the Street evenL entitled 'NutritKJn and exeruse as important factors for the proFer function of the biochemical melabolism., and open to members of the public.. providing SUPPOrt. conststuting a granl of é1,500, to 2 constituent scoety events and activrties being held in 2023.. the Croatian Souety for Biochemisty and Molecular BK)logy IHDBMBI for their event 'Contribulion of bioscience to the green Iransrtion, (held in May 2023) and the Portuguese BlocheM￿al Society ISP8} open $ymposiurn and exhib￿"On enbtled 'Exploring RNA %Autions to infethous and non-communi¢able diseases, (held November- December 2023): Participation in Biomedical All￿nce activibes. Through active participation in activities of Biomed Mlianc£ {General Assemblies, Policy offi￿15. meetings and tssk for¢esl the S&S Committee contributed in several suggested dtjcuments for the shaping of European policy, induding participating with other organisations lo obtain from the EU the best research budget for the Framework Program FP9. Iniliat've for Science in Europe IISEI xtiviti'es.. active negotsation for the rejoining of FEBS wrth ISE, following the activities of the federatK>n in the earty of 2023 as observer and then as a full member. Participation in the FEBS NetW￿rk. Education The Education Committee has the mission of promb'ng education and training of the highest quality in molecular life sciences in Europe at tijlh undergraduate and postgraduate levels. The committee's activities include.- organizing and fvnding educab.on events, running the EdUca￿n Ambassadors inibats"ve, supporting the open access joumal FEBS Open 8￿'S seth.on devoted to educats'on and overseeing and contributs'ng lo the Educator Channel on the FEBS Ne￿Ork. FEBS Education Committee also works collaboratively wth FEBS AdVan￿d Courses Committee and FE8S Careers of Young saenb.sts Committee. This is the report from the Chairpefson, Prof. Ferhan Sagin on Education Committee aCtN￿"eS held in 2023. Education Committee M•eting5". the committee met in-person in May 2023 in Vilnius, Lrthuania prior to the Ambassadors Meeting.. the other in-per50n meets.ng was in Frascati. ltsly in November 2023,. additionally. online meetings were also hekl. Page 7 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCEfiES (A Company Limlled by Guarantee} TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 7th FEBS Education Ambassadors. Meeting The 7th FEBS Edu¢ation Ambassadors meets.ng took place in Vilnius, Lthuania on 5 - 6 May 2023, with 28 ambassadors in attendance. The meeb'ng program induded on day one". 4 sh¢)rt presentations from ambassadors sharing their edu¢ation actr"vrties in the past year. a panel discussion on hot issues in education including. Guiddines of teaching biochemisty in various graduate degrees., 'Training of young scientists regarding ethical iSSLtes in research and gc*Jd lab practices.. 'Digital teaching in biochemistry education,. 'Motivab'on of students to enter molecular life suences programs. and 'ChatGPT in teaching and leaming and on day I￿0 the topics induded. Teaching with debate.. Visual competence in biochemistry., 'TBL in biochemistry teaching and 'Science fiction becomes Ivirtuall realty.. aPpI￿a￿n5 of VR in research and training.. There was also a 'Meet the Expert. session across 4 parallel room5. Sponsored Edu¢alion Amba$8ador Events The FEBS Educab"on Committee sponsored 2 events. organized by FEBS Education Ambassadors.. the ambassador from the Association of Biochemists and MolecuLgr Biologists of Bosnia and HerLegovina organised 1-day educats.on event on 18 May enlitled 'lnnovats"ve teaching as a basis for Excellent Research in Biosaences., held prior to their swety's first Congress. which was attended by 100 young researchers and edueators and attended by some members of FEBS Execukn"ve Committee". and the ambassador from the Lafvian Biothemical Society, organised an event entitled 'Besl practices in leadership and student menlonng in life science research. in Ri9a. Lats*ia on 20 October. Fre• Education Bite Size initialive Launched in 2022, short online sessions were hekl in 2023 with a hands-on and Q&A4ed approach with the tile 'How to ests￿l$h an education ¢omrnittee wrthin your socieW Challenges & tip$'. Educallon Committee Seasonal Wèbinars The seasonal webinar series which stsrted in 2021 and o)nts'nued in 2023. featured". Winter webinar entitled 'Assessment 101 and beyond in Life Sciences educalion.: Spring webinar enb.ded 'Ethu al the heart of the training of s¢ienkn"sts.' a cruoal issue for the future of ￿Sear￿,. Summer webinar entitled The importance and process of integratsng Al into teaching and ￿aMing,. 47th FEBS Congms Edu¢ation Activities FEBS Edueation Committee organised various actr¥itses at the 47th FEBS Congress". 11 FEBS Education Committee evening event entitled 'FEBS Stands Up for Education". Hot Topics, Music and More.: 21 Education posters and speed talks featuring 23 posters on under9￿auate postgraduate texhing.. 31 an educalion-lhemed treasure hunt. Contribution to FE8S Network Several posts were Pu￿1Shed on the FEBS Net￿rk Educator channel in 2023. induding." 'Bringing undergraduates into the peer review community using preprints. 'Lecture capture affects student learning behaviourf 'Al is here, what does that mean for biosuenee education?. 'Inspiring innovation, together. Learnsu" achieves King's Award for Enterprise. 'Leadership for under￿Presented trainees". the LeaP program. 'Ethics at the heart of the training of S￿entr"sts.. a uucial issue for the fvtuR' Educatlon Committee Workshops 3 Education Committee joint workshops were held in 2023.. wrth the Biochemical Soryety (UK} and in asS￿al￿an *ryth IUBMB, hekl in Manchester, UK on 2&26 May, and entilled 'Evofving Molecular bioscien￿ educat￿n,. with the Slovenian Bicchemical SLxiety. held in Ljubljana and PortorDz. Sbvenia on 19 and 21 September, as part of the 15th Meebng of the SBD., with the Portuguese 8iochemical Society. held in Aveiro. Portugal on 12- 13 October. and entitled Page 8 THE FEDERATION OF EUROPEAN BIOCHEf•llCAL SOCIETIES IA Company Limited by Guarantee) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 'SymF#)sium on Pedagogical Innovab"on in BKJsaences- Hu* to Engage Students in our Practices?. ContrIbutlo￿ to the 2023 FEBS Young Scientists. FONM The Education Committee Chairperson partiopaled in one of the Career Skills pyactical sessions of Ihe 2023 YSF (held in Tours, France), giving a lak entsded 'Educator Skius.. Integratlon The Integration Commfftee. which was chaired in 2023 by Prof. Jerka Dumie, continued its outreach and support for scientists in European countries with economic challenges andlor no existing or xb.ve biochemical society, as well as actNil*s for integrats.on and collaboration tetween all FEBS socEties. Activitie8 of the Integrntion Committee during 2023 Inc￿ded. following the launch of the Member Scaety Representatwes IMSRS) initiative in July 2022. this initiats've continued in 2023 with regular online meeting$ and all MSRs- one from eaeh FEBS member society137 in total, not including Belarus and Russk4 as those soc￿tieS are suspended from FEBS activities) - joining together in person at the FEBS Congress 2023 as an opportunty to learn more at ffirst hand of FEBS aGlivibes and lo receNe data compiled by FEBS on their soaety's participation across FEBS different even15 and initi'atives Wth the purpose of enhanong their soC￿ty,5 engagement with FEBS, to network with each other and to contribute to a dedicated MSRS session in the Congress program. Other MSRS activitses during the year included a dedicated 'room' on the FEBS Network plalfom to share good practice and ideas, and a detailed suNey for FEBS to leam more about their society's current level of activity particularty since emerging from the pandemic and to more abjut what their society values most from its memtership of FEBS. FEBS provided limited support to each MSR for them to attend the Congres$. 32 of the 37 MSRS attended the Congress in Lisbon and MSRS meeting. 1nits.ated for the 2023 FE8S Congress. the Scientffic Advisory Committee was chaired by the Integrab'on Committee Chairperson and comprised the MSRS from each FEBS member society (excluding Belarus and Russia) lo propose names for the saentific program of the 2023 FEBS Congress. The initial SAC was a success and was continued for the developmenl of the 2024 Congress scientific speaker program. IUBMB-FEBS-FASBMB PROBl￿friCa Fellowships." the Integrat￿n Committee Chairperson coordinated this new fellowship scheme. in conjunction wth the Fellowships Committee Chair, whereby FEBS contributes Q5.000 and IUBMB contn"bules Q5,000 to the fund for fellowships open to eligible applicanls wrth a PhD and postdoctoral fellows in Afr￿an countries affiliated with FASBMB to work in a laboratory in a FEBS rftember sc¢iety Country for up to six mnths with an award of É7.000 comprising É2.000 for travel costs and ES.000 for living ¢osts during the fellowship. 15 applications were received in Ihe first call, with 9 eligible for awards. A delegation of the ￿mmIttee and other members of the ExecutNe Committee visited the Scxiety of Biological S¢iencÉs in Cyprus in May 2023. folk)wing the soaety having joined FEBS membership in 2022. The visrt in¢luded three universities, both stste and private, and three institutes. including the support system for scientific research in Cypnjs. the Working Group on Integration (￿￿1) Chair attended the Education Committee and Education Ambassadors meeting in Vilnius. Lithuania in May 2023 and attended Ihe FEBS-IUBMB-ENABLE Conferen¢e in Cologne, Gem)any in October 2023. working with the FEBS Fellowships Committee on the co1￿￿)ratIve Developrr*ntal Scholarships criteria for the exclusive benefit of PhD students in ￿rtain FEBS countries with HINARI IResearch4Lifel status and 2 We￿ awarded for the 2022-2023 year (the programme was discontsnued for new applications in 20231, the WGI Chair actively led on new initiatives to increase collaboration and engagement with FEBS member socieb'es and collaborated with other Committees and w(wknng group5. As part of the WGI a￿"v￿.e$ arKI the FEBS Congress. financial supw)rt was given under the 'Sprinzl Scheme. with a 50•/0 registration fee discount to 5uentists resident {siudyinghvorking} in Armenia. Bosnia and Herzegov¢na. Georgia. Moldova. Morocco. Serbja. Tunisia and Ukraine to attend the 2023 Congress. Page 9 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Cornpany LIMIt￿ by Gu•rantso) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Womon in SGienc• The planned activit￿S of the Working GrtyJp on Women in Science IWISE) with Prof. Dame Caroline Dean as Chairperson in 2023, We￿ as follows.. The FEBSIEMBO Women in Science Award, now in its sixteenth year, recognises and rewards the exceptional achievements of a female researcher in molecuLar biok)gy gNing parbcular attention to the previous five years. Winners of the award are role ffK)dels who inspire future generats.ons of wO￿n in ￿enCe. The 16th meeting of the FEBSIEMBO Women in Science Award panel was he￿￿ in January 2023 to review the nominations received for the FEBSIEMBO Women in Science Award 2023. Of the many excellent ¢andidate Cvs. there were three clear favourites and. based purety around ￿lents"fiC achievement, the panel decided to award the prize to Sarah Teichmann for her fundamenlal contribut￿n$ in drffe￿ftt areas of biology, as well as transformative melhod developmenL The panel agreed it wouhj be better to meet in person and see the winnerfs presentation, so from the 2024 Congress onwards the 2025 wnner ￿11 be thosen during a meeb'ng of the panel at the preceding Congress. where the panel can also partupate in the Women in Science ath'vitj'es al the Congress, which included the ne￿rkIng lunch for 50 Congress parb'upants to discuss Women in Science issues. The 2024 winner will be osen earty In 2024 and presented with the award at the FEBS Congres5 in Milano. A future rotation of the panel members wa5 also agreed (after a three•year tenu￿} induding those members nominated ty FEBS and by EM80. OBJECTIVES AND ACTMnES FOR THE PUBLIC BENEFIT The overall obje¢tive of FEBS is to contribute to and promte the advancement of ￿SearCh and education for the public benefit in the xien¢e$ of bicrhemistry, molecular b￿c#3Y and related disryplines. As indicated by the spe¢Jfic key obje¢lives of FEBS set out at¥)ve under'objectives,, FEBS does this part￿UladY through.. funding forums for presentatr.on and dis￿5510￿ of research results and related areas of interest al its large annual Congress. Young Scientists, Forum {YSF), FEBS Fellows Meeting, Special Meetings and other Advanced Courses." promoting training through lectures courses, workshops and practical courses of its Advanced Courses programme. as well as its educatr.on Wofkshops,. and supporting partiapation of promising young scientists in these events through YSF awards. Youth Travel Fund grants and Congress bursaries., facilitating and supporting the exchange of scientffic infomiation beiween biochemists and molecular biolcgisls especially in Europe and other countn.es of FEBS Constituent Societies pnncipalty Ihrou9h these forums and mechanisms. but also through Consts'tuent Sw"ety meetings {Nab"onal Lecture scheme), FEBS3+ meetings, FEBS Fellowships {which promote mobility), and schemes io support integrats.on of biosryentists working in ecorKJmically disadvantaged counth.es of the FE8S area,. providing stipends through Its Fellowships programme to allow resear¢h to be carried out in host laboratories by talented early-career scientists.. offering high-quality publicab.on of ￿tsearch findings for both authors and readers through its four intemational molecular lrfe saence joumals. Through the many activrties of FEBS outlined above, the benefiaaries of FE8S indude SC￿nti$ts at all levels directly engaged in research and educab.on in the molecular lrfe SeEn￿$, and ultimately humankind across the gtobe through the conlribub.ons of these areas of suen¢e to human health, agriculture, biotechnology and related areas. and enrichment of human knowledge. FEBS whoNy owns its intemalional ioumals. wthich are of importance to FEBS both by di￿¢t￿ contribub'ng to its objectives and as a SOUTce of income to support ils other purposes. FEBS fomows all direclives on Open Access publishing from the UK. EU and ￿levant researth funders across the wortd. Two of the FEBS publications - FEBS Open and Molecular On¢ology- are fulty open access. Its hvo hybrKI joumals - The FEBS Joumal and FEBS Lette￿- offer authors open access options. often with no direct ￿$t to authors at institutions with a Page 10 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarantee) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Iransfomiabonal agreement. In additton. authors are able io deposit a¢¢epted research arttdes, as required by funders, in institutional reFosilones. through which they are accessible lo th• public. and all published ath'cles in our hybrid journals are freely available after 12 mnths to all feaders. FEBS events a￿ normally open to scientists throughout the world. Reopients of FEBS grants for fellowships and for support of participation in meeknngs are normally required lo be members of FEBS. Constituent Societies (where membefship critena are those expected of leamed soaetiesl and resident within the FEBS area of Europe and neighboLtring countries. son￿ FEBS programs particulady benefit disadvantaged scientists. The trustees conf mi that they have refer￿ to the guidance contained in the Chanty Commission's general guidan¢e on public benefit when revwing the organrLation's aims and obJ"eth'ves and in planning luture activities. Grant Maklng Policy The overall objective of FEBS is to contribute lo and promte the advancement of research and education for the public benefit in the molecular life sciences and related disciplines. Policies for key grant5 awarded by FEBS to achieve these goals a￿ oulined below. Fellowshlps As part of our commitment to young scientists under the FE8S Fell¢)wship program set up in 1978. and to further research in the molecular life sciences. we offer Short-Temi Fellowships to members of Constituent Societies, as well as Summer Fellowships to promising MasterslPhD students. The new FEBS Excellence Award program was launched in 2021. It is intended for eatyvcareer saentssts vtho have Pls in their Host Insts"tulion for al least one year and are in a salaried capacity. As part of our Fellowships program, we also offer scholarships designed exclusively for members of our Consb"tuent Societies based in FEBS countnes with HINARI IResearch4Lifel status. Our Fellowships are intended to allow members of our Constituent Societses working in a FEBS country lo work in a laboratory in another FEBS country. Eligibility criteria for FE8S Fdlowships are set out in detailed guidelines on the FEBS website. The inits'al appli¢alions for Fellowships are assessed on merit by the FEBS Felk)wships Committee. Within three months of mplelion of all Fellowships. awardees are required to prepare a final report on the work caffied out during the tenure of the Fellowship. Similarfy, Excellence Awardees are asked to provide both a scientific and a financsal report lo be eligible for the 2nd and 3rd instalments. Grants for organising FEBS Adv•n¢•d Courses Grants for organising FEBS Advan¢ed Courses (including lecture courses. workshops, pra¢tr'¢al Courses and special meetings) are awarded to senior xienb.sts by the FEBS Advanced Courses Committee on a ¢ompetitive basis. Reports (including s¢ienbfi¢ and financial) from the organisers are reqUI￿d wrthin 3 months after the event Grants for young sci¢nti$ts attending Advan¢¢d Courn¢s Students participating in FEBS AdVan￿d Courses {induding lethire courses. woTkshop$ and practical courses) may apply for financial support thrwgh the FEBS Youth Travel Fund (YTF). In 2023, grants were made to persons travelling from their current country of residence to another country. mosdy in the European a￿8. Appli¢ants for these grants should nomialty be registered as a student al an institution of higher learning in a country where there is a FE8S Consts"tuent S¢xiety or be within five years of having completed a PhD thess. be a member of a FEBS Constituent Scciety. and not have receNed a grant from the Youth Travel Fund lo attend an Advanced Course in the current or pre￿dIr￿j year or receNed a grant lo attend the Young Scientists. Forum in the current year. Candidates are shoruisled by the Course organizers on ￿￿TIl. Grants for oryanislng the FEBS Congress and FEBS3+ meetings. and requests for Natlonal Lecture support FEBS evaluates bids for organising ils yeaty Congresses and also FEBS3+ meetings. as well as requests from Consbtuenl SO￿eties for Nabonal Lecture support. acLording to their quality.. the administrative responsibility for these is wi the hands of the FE8S Congress Counsellor IProf. Piotr LaKller in 2023). Page11 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Lim6ted by Guarantee) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Grants for attendtng the FEBS Young Scientists. Forum and Congress (YSF awards) Recipients of YSF awards are sewed by the Chair of the Careers of Young Scient15ts Committee {Irene Dlaz- Moreno in 20231 and the local organising committee on mert( with eligibilty criteria that nomally indude.. ilbeing a PhD student or postdoctoral fellow within S years of finishing hi￿eT PhD at an institution of higher educatr'on in a ¢ountry where there is a FEBS conststuent Sooety., ii) being under 35 years old.. iii} being a membei of a FEBS Constituent Society.. not having attended a recent YSF, and not having receNed a Youth Tiavel Fund award in the same year. Congress butsarles Recipients of bursaries Iwhich offer financial support wilh registration, travel and a¢¢omrnodatson costs for the Congress) are selected by the host $o¢iety of that yea¢s CorKJress on ff*rit. with eligibilty criteria Similar lo those for YTF and YSF awards. Page 12 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Llmlted ty Guarantee) TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDED 310ECEM8ER 2023 A¢hiovement and perfonnance This section summarizes and assesses our principal athievements in 2023 against the formal objectives of FEBS. More detsils ofthe athits.es included in l)nef here can be found in the'Acts'vrties' seth'on above. Objectivg 1: holding and arranging congresses, training and educational courses on matters connected with bio¢h¢mistry and molecular blology and related dlsclplines FEBS Ad¥ane•d C*iwses 16 FE8&sLtFWrted events ￿re for 2￿3.. 7 Alfvanced Lecture Courses, 1 joint FEB￿mB0 Lecture C(Mxses. 2 Praclical Courses, 1 comts.ned PraclKal and LecbJe Cwrse4 2 Speud Nleews 3 Workshops In 2023, FEBS ¢￿tsnUed k) fU￿j several Atha￿j Cwr5es wth high scienlific conlent and al￿ funded YfF grants lo aknv parfr.ripaI￿ of youry researd*r5 al FEBS cwrse5. The assessn*nt woceth for course sek(￿n aThl funthng ned, online dal*Jase for a￿Ka1￿)n5 aThJ rerNJtiNJ emhanced, FEBs4Tr¥r￿d and branded course *tbsites introduceAI aThl colaboraborts wilh EMBO and IUBMB coNinued. FEBS3+ Meetinglsl: High Tatras, SloVa￿a September 2023." the KXWI Bhictherimsty Congress me&"ng Ibjsled by the Slovak s￿ety, in (£ffli￿KlTh1 wth ts ￿eMber￿je￿$ of Ihe Cz&h RepuLliq Hurvjay aKI UkTain FEBS 3+ meelings receive SUFPJrt corryNry É10.OCKJ tothe h(sl lor ger￿31 rT*etwwJ Or9￿1zat￿￿ and É10,[￿ SUFVOrt Ihe attendance ol yourg saethists frLKn the other parncipab.ng ￿Cle1￿5. 22nd Younll Sd•nllsts Forum IYSF) and 47* FEBS Congress: The 22￿1 FEBS Young Soentsts. Fcm look place in Juty 2￿23 in Tours, FrarKe, pr￿rI0 the Conws uwl ts %￿n11Sts in cz￿ Repubfiq Hunwy, IDvahia Ukraine" enhanced Imks belweenthese EBS Consti￿ent &(jet￿5. See 'SupFQrt for nsb"luenl SOW evenW seclw for more deta￿$. The YSF induths over 1CKI PhD students and youThJ pK)sl(kJcs, whose attendance al llis and the Cwress is lunded by FEBS YSF ayrdrds. In Jdrfion, FEBS supwrts parbcipatsDn of a large rwJmL*r of y(wng scienlBts in its annual Congress throu￿ the FEBS Bwwies scheme. The 47th Cwgre55 wa5 hebj m T￿ls. Fra￿ in Juty 2023. annual ￿s Contye55 PIOVKks a IOT inlematronal scientrfK exthaffje arKI sh￿aSe$ Ihe newest develowents in tMochem151ry. mclecular b￿￿09Y and related *eas. The Coryress conwrises plenary lectures, sympo4 PDsler sessions, wo)*shops and oth tiv￿￿$ on related ￿pIcS The CorKJiess ts hekl countrtes a Constitijffil Scoety of FEBS. Page 13 THE FEDERAMON OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Llmlted by Guarnnteo) TRUSTEES. REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 Objectlvo 2: facilitating and supportlng the exchany ol scientlfic inforniatlon between biochemlsts, molgculaf biologists and scientlsts working in related disciplines generally and especialty in Europe and other countrles of Constituent Societies Comn*nts FEBS Coiw, Ath4ano•d Cow5•5 •nd Education Wutshops Effective enhancement of reglonal. nauonal and INernatlonal mee15ngs by furKknJ ol dLstsngutshed $Feake￿. Nayonal Lectures awarde(J lo natthal rW ol the rn￿0er societles fr(wn Bosnla aThJ Herzegoln4 W, RomanL4. Sh?￿la, Sp*) aThl TDrktye. Otherrneetlng sponsoT5hlp The FE8S WorfdwA¢Je LeL*re al tr* 27th FAC6MB C￿l￿ence In ThailaThJ in Novembw 2023. Ernir￿nt speaker5 for speLyal events #J meeunqs beyuKI Éurope, whlch also alowed collat*xation ￿1h kntematK)nal organvzations and y*k1ed FEBS joumals, rrfonxl1w￿. Achl•v•ments Comments FEBS Fellowshlps Fell0V￿ move towort In lab kn drfIerertc￿nty (see Ob*(tht 3 below). WGI schém•s SupFKKt lor ￿Mun￿e$ of rThYegJl¥ Iwe sdenti5ts In European Gounlrie5 wlth econornic thallenges andlor ￿ extsling or aciNe bKthemKal so7ety through visrts, Con￿eSS.spTknJ Schem¥. EthJthn Vlortshcys and CDS FellOY￿1pS as well as encouraokni Ihe eslablLshmeN (4 new so*ties and for them to beneffil from FEBS. prOr￿￿On ol exchange of sk11￿kn1YIAedge. Cothbute5 to develcy1rylmalntsl￿￿9 ro)1 of effethe researchers In Europe. Objectlve 3: facilitatlng and supportlng the training of young scientlsts In research, In the form of fellowships Short-Tgnn FoIIow8hlps 24 Short-Temi ar￿ 11 Surnrw Fe1k1￿h1ps iaken up. ErthaiKes researL* p0551blll¢*S for young $C￿n￿Sts. nuntrrs awwded In a(wrdance wlth buaoew limNS. Long- Yemi F•llo*3hips 3 L￿￿Tem) In po￿. Very ￿[r￿e1111¥e_ onty the most outsiwding scleniists ￿￿$ll￿., nltmbers awarded In accordan￿ vAth tary I[Th￿ts. Acoxnts loi major part of FEBS expernYIlu￿. Thr6 prL*3ram was ¢J¢gcDntlnueiJ as of 2021. Very tx)mpeVUve- onty Ihe most outslandlrwJ sderrf15ts sw¢xsslul.. tw must be rec4yanL2ei1 sdeniists In thelr and SWJ kKtssess an out$tsndif¥J traL* rewro. Parltc4wts are Invlted to partlcwte. No sele¢lknn procedure apF*s as OW Gurrent 8nd past FE8S Lona- Tem Felbws aTe ellglb*. The organtratrm costs a shwed with YSF. Excellen¢• ATArynle•s 10 In p)st. Fellows IA••ling (last hdd In Vlmello, Ptriugal thjty 2022 kn conlunu th the Young Sdenusts FoFurnI 17 Djrrent and lor LTFS accepted the Invltattrm. The next Fell0*45 rne¢￿r vhll be held In Pa￿a. ttaly In kne 2024 lor Cufrent ÉxcelenGe AwJroees and 2 flwmer LT Feiknbs. Page 14 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarantee TRUSTEES. REPORT ICONTINUED FOR THE YEAR ENDED 31 OECEM8ER 2023 Objectlve 4: ¢)rganlslng the"edltlng and publlcatlon 01 sclentlfic vegearch and educatlonal materfal In biochemistry and molecular biology and related disciplines Comm•nts Our loum*s cont11￿e to makntaln h*3h siandaits of PEer review. Sevaity- one per cent of all 4￿cke5 publlshed open access Ip)Id OA¥ r*J pertarmanc* of FE8S' Press ma& In a Ghallenoinq 5denific 11sNng envlronment. The ¢urrent Publishing Agreement be￿een FEBS and Wiley runs 2016-2023. The eight-year contract is based on revenue share, guaranteed income and Speci￿ support for the FEBS NetsvorL A new agreement with Wiley is in place and started in 2024. FINANCIAL REVIEW Journal Income and costs Total income from royalties in 2023 (￿.45m) was 3.9% higher than the royalty income in 2022 1É7.17M}. The total costs for the four FEBS p)urnals, FEBS Joumal, FEBS Letters, FEBS Open Bio and Molecular Oncobgy remained the same in 2023 as 2022. These costs include the direct costs of employees working on the joumals and editors, payments. Distribution of •xpenditur¢ on FEBS activities In 2023, Fellowships remained by far the highest area of charrtable FEBS spending É1,038,476 1É894,000 in 20221 then Advanced Courses, course grants and YfFs totalling 4353,425." {45C6,000 in 20221. Prizes and awards for excellence in molecular life saences totslled 435.000 (439,000 in 20221, and funding of lecturers for meetings wthin and outside of Europe totalled 432.000 I-S4,000 in 20221, including one FEBS 3+ meeting. Several other areas of FEBS work- induding education workshops. science and society sessions, and 'inle9ralion' initiatives-were undertaken for ￿134.(￿)0 l-Q8.000 in 2022} in total. Govern*nc¢ and support ¢osts The senior seientisls who serve as FEBS Officers and members of FEBS committees all work pro bono, and the holders of key positions in the FEBS ExecLttive Committee generously devote considerable time and energy to FEBS activities. There are a small number of support personnel working in the FEBS Central Administration Office dealing wth central administratr.on and communica*"ons. the FEBS Treasury Office dealing Wlth financial matters, and those working wth the Fdh)wships and Advaneed Courses Committee Chairs to support their work and those of the committees. The total governance costs - i￿luding tre expenses assoaated hbgher-level commfftees {Council. Executive and Finance) within FEBS. Central Administrabon Offi¢e, The Treasury office and Secretsry General expenses. as well as auditor and other professional Serv￿ fees - amounted lo about É839,000, 1230h 2023 Gompared to 17•/• in 2022) of the size of charttable spending in 2023 {É3.6M, note that these goveman¢e co$ls are not included in the totsl for charitsble spending). An indication of the supp)rt costs involved in running the acts"vities of FEBS with the highest expenditure can be given by the committee expenses as a percentsge of the charitable spending in that area.. in 2023. this was approximately 5% 17% in 2022) of the total Fellowships grants. and 17% (11% in 20221 for Advanced Courses grants. Support ¢osts for the journds are Covered in'Joumal income arKI costs, above. Investment perforniance In 2023 after an in41eplh review of its investrnent portfolio. the Finance Committee of FEBS held a tender for the management of its portfolios. The tender was conducted by the Finance Committee, plus the Ex-chair of the Advanced Courses Committee, with the assistan￿ of an independent investment c(Jnsultant. As a resull of the tender, neafty É30 million of the portfolio was moved from JPM to Cazenove by the end of 2023. For the ￿efve months lo the 31 December 2023 the investrnent portfolios held by FEBS. investrnent managers achieved a relum of +9.4°A1-11% in 2022). Page 15 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Llmltsd ty Guarantee TRUSTEES. REPORT ICONTINUEDI FOR THE YEAR ENDED 31 DECEMBER 2023 PRINCIPAL RISKS AND UNCERTAINTIES The trustees have a duty to idents.fy and review the risks to which the charity is exposed and lo ensure appropriate controls are in pba¢e to provide reasonable assurance against fraud and error. Reduction of income due to changes in journal publishing In addition to directly fulfilling one of the charitable objecuves of FEBS, our journals have provKled a source of income lo fund FE8S' other chaiitable work There is a risk of reduction in income due to the loss of traditional joumal subscriptsons as publishing moves to new open-aecess models, driven by lunder mandates for open access publication. The transformational dears negotiated ty our publishing partner, Wiley, are aimed at protects.ng joumal income as library conlracts move from sUbscript￿nS to open acce$$ publishing models. Nevertheless. sorrE attn.tion of tradth.onal sub5CTipti¢)n income is expe¢ted due lo library budget culs and Ihe increased proportion of open access content joumals. FEBS is addressing these concems by {1) its wlicy on reserves (see below) so that future income can be derived from investments and {21 ts negotiated long4enn contra¢t wth a commercial publisher which, in turn, is negotiab.ng deals wth libiary and funding consorb"a that combine open access publication rights with traditional 'reading access lo the FEBS Press joumal. The FEBS Publicat￿n5 Committee has made strategic planning on how joumals adapt best to new publishing requirements. Inv•stm•nt Man•gom•nt All decisions about investments are made by the Finance Committee, as delegated by the Executive Committee. On occasion the Finance Committee may seek further approval from the Executive Committee on significant investment commitments. IDt•rn•l Conlrols FEBS, systems and pmeesses are monrtored regularly. The Finance Committee is responsible for maintsining proper accounts'ng records which disclose wth reasonable accuracy al any time the financial position and to enable them lo ensure that the finan¢ial statements ¢ompty v￿h all statutes and regulations. FEBS, controls include regular internal and extemal overS￿ht and checks. Controls and procedures are appropriate for the Ofganisation's slle and operatson. FEBS uses automated ￿OUnting sofvare from a large. reputable supplier and The Treasury department has several processes to ensure the appropriate use of funds, the management of the accounts and recording of all tranSaC￿nS. Dubes wrthin the Treasury a￿ separated, and Fobusl systems of oVers￿h1 and authorisalion are in ￿aCe. Imp•¢t on overall obj•¢tives The success of FE8S in prornling the advan￿￿nI of research and edl￿atrOn for the public benefft in the sciences of biochemistry. molecular bh)logy and related disciplines is carefulty monitored by stringent peer review and other methods. PLANS FOR THE FUTURE Reserves policy The total value of fvnds hekl by FEBS at 31 December 2023 was É99.2M (E89.3M in 20221. None of the fvnds were restn.cted funds or unavailable for the general purposes of the charity at the end of the reports.ng period and no materia arrthnts have been designated or are othepmse committed as al the end of the reporting period. AS at year end 2023, approximately 81% could be realised in fewer than 3 days, 10% in investments that may be realised in 10 years and the rest had varying timescales. up to 6 months, in which the assets may be realised. The investments in private equtty and infrastructure are illiquid over a short timescale. These investments will be held by JPM for up lo 10 years and up to 8% of the totsl investment portfolios will be held in private equity and 5% in infrastructure. Page 16 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantse) TRUSTEes' REPORT (CONTINUED) FOR THE YEAR ENDED 31 DECEMBER 2023 The Treasurer of FEBS, regulady revws the perfomiance of FEBS investments during the year. Significant changes in investments and the trealmenl of funds are discussed and approved by the FEBS Finance Cornmittee and where appropriate, are submilled for fvrther approval from Ihe FEBS Executsve Committee. The FEBS, reserves policy alocates É4M for one yeaf $ essential fijnding this 1$ held in ¢a5h at the bank. The FEBS Trustees have approved the enhancement of the investment portfolio to reach a value that may generate fvnds lo offset potential changes in income due to the new publishing model. The income fnjm the portfolio in addibon to royaty in¢ome wll ensure that FEBS exists in perpeluty pfovKling funding for the running of the joumals and its other charitat4e activities. Impact of COVID-19 In the short lo medium tem COMD-19 did not have an impact on the major sour¢e of FEBS. in¢ome whth is the royalties from FEBS. j¢Jumals. FEBS did not incur any additional costs due lo COVID 19 and its day-to-day operations were carried on without a major impact. No employees of FEBS were fvrloughed and no govemment grants or loans were sought or received by FEBS in relation to COVID-19. One of FEBS tharitable aims is to support life sciences Ihrough its events and in 2021 these actNtties were ujrtailed. as they were in 2020. In these cases. the grants that were not paid were rolled over to fund activities in 2022. As a resu￿. expendilure for 2022 ts higher than 2023. due to the number of events postponed from 2020 and 2021. Future commitinents and plang for ¢ther areas of FE8S w¢>rk We now have firm arrangements for a programme of Annual Congresses until 2026. as these involve substants'al forward planning. Expenditure on thanc£d Courses up to 2025 and the tosts of annual extensions of FEBS Ex¢ellen¢e Awards lo up to 3 years for awardees already in post are induded in our budgets. With regard to fvture activibes, we are also continuing to attempt to forge closer links wth related European and woddwide organisab.ons that cover ConbgUou￿0VerlaPpIng areas of molecular life sciences le.g. biophysic5, microbiobo9y. imrnunology, eancer) wth the aim of maximising the use of our impact5 and resources. Concluding Comments FEBS has continued lo operate successfulty in pfornoting the advancement of ￿Search and education for the public benefit in the sciences of biochemisty, molecular biology and related disoplines, and ils cu￿ent strategy for its long-lerm survival is progressing smoothly and according to plan. By making provisions with its reserves FE8S will be in a posrtion to provide support to many researche￿ in yws to u)me. Approved by order ofthe members of the board of Trustees and sNJned on their behaw by: Professot M De La Rosa Tru$tee Dale.. 09109124 Page 17 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarant•el STATEMENT OF TRUSTEES. RESPONSIBILITIES FOR THE YEAR ENDED 31 DECEMBER 2023 The Trustees {who are aLso the directors of the Company for the pur￿SeS of company law) are responsible for preparing the Trustees. Report and the financid stalerrRnts in accordance with applicable law and United Kingdom Accounting Stsndards {United Kingdom Generalty Accepted Accounting Pracb"cel. Company law requires the Trustees lo prepare financial ststements for each financial . Under company law. the Trustee5 musl not approve the financial statenEnls unless they are satisfied that they give a true and fair view of the stste of affairs of the Company and of rts incoming resources and applicatson of resources, including its income and expenditure, for that period. In preparing these financial statements, the Ttustees are required lo.. select suitable accounting policies and then appty them consistenuy.. observe the ryEthods and prinryples of the charib.es SORP IFRS 1021". make judgments and aC￿unting estimates that are reasonable and prudent. stale whether applicable UK Accounting Stsndards {FRS 1021 have been followed. subject to any material departures disclosed and explained in the financial staternents,. prepare the financial statements on the going coneem basis unless it is inappropriate lo presume that the Company will ￿ntIn￿ ￿ buwness. The Trustees are responsible for keeping adequate accounting records that are sufficient lo show and explain the Company's transath.ons and disclose with reasonable ae¢ura¢y at any b'me the financial position of the Company and enable them to ensure that the financial statements Comply with the Companies Act 2006. They are also responsible for safeguarding the assets of the Company and hence for taking reasonable steps for the prevention and detection of fraud and other iffegularitses. Approved by order of the membws of the board ofTrustee$ and signed on ts behaff by.. Professor M De La Rosa Trustee Dale.. 09109124 Page 18 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Llmiled by Guarantee) INDEPENDENT AUDITORS. REPORT TO THE MEIABERS OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES OPINION We have audited the financial statements of The FederatÉon of European Biochemical Societies (the charitsble companWI for the year ended 31 December 2023 wh¢ch comprise the Ststement of Financial Activities, the 8alance Sheet, the Statement of Cash Flows and the related notes, including a summary of *gnificanl accounting policies. The financial reporb.ng framework Ihat has been appiied in their preparatron is applicable law and Unrted Kingdom A¢¢ountsng Standards, induding Financial Repo￿ng Stsndard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland, (United Kingdom Generalty Accepted Accounting Pract￿). In our opinion the financi￿ ststements.. 9ive a true fair view of the state ofthe thartsbbe companls affairs as at 31 December 2023 and of its in￿ming resources and aprAi&￿10n of resour￿$. including its income and expenditure for the year then ended.. have been Pro￿ty prepared in accordance with United ￿"ngdoM Generalty Accepted Accounting PraGtice,' and have been prepared in accordance wth the requwements of the COffy￿1eS Act 20(￿. BASIS FOR OPINION We ¢ondu¢led our audit in accordance ￿th Intemational Standards on Audiling {UIQ IISAS {UKI) and applicable law. Our responsibilith'es under those standards are further described in the Auditors. responsibilities for the audit of the financial statements secbon of our reporL We are independent of the charitable company in accordance wrth the ethical requirements that are relevant lo our audit of the financial statements in the United Kingdom, including the Finanaal Reporb"ng Councifs Eth￿1 Standard. and we have fvlfilled our other ethical responsibilrties in accordance wrth these requirements. We believe Ihat the audit evidence we have obtained is sufficient and appropriate to provide a ba%s for our opinion. CONCLUSIONS RELATING TO GOING CONCERN In auditing the ffiftan¢￿ statements, we have conduded that the Trustees. use of the going concem basis of accounts'ThJ in the preparation of the financial slalements 1$ appropriate. Based on the work we have perfonred. have not Mlentified any material uncertainties relating to evenls or conditions that, individually or collectNety. may cast signfficant doubl on the charitable company's ability to continue as a going concem for a period of at least ￿e1ve months from when the financial State￿￿nIS are authorised for issue. Our responsibilities and the responsibilrties of the Twstees with respect to going concem are described in the relevant sections of this reporL Page 19 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarantse) INDEPENDENT AUOITORS. REPORT TO THE MEMBERS OF THE FEDERAnON OF EUROPEAN BIOCHEMICAL SOCIETIES ICONTINUEDI OTHER INFORMATION The other infom*tion c£*mprise$ the inf0m￿tIon induded in the Annual Report other than the financial ststements and our Auditors. Report thereon. The Trustees are responsible for Ihe other infomialion contained within the Annual Report. Our opinion on the financial stslements does not cover the other information and, except to the extent otherwise expliciuy ststed in our ￿ port, we do not express any fomi of as$urance ¢onclusion thereon. Our responsibility is to read the other informabon and. in doing so, consider whether the other infomialion is materialty in¢onsistenl with the finanaal stslerr£nts or knowledge obtained in the course of the audit. or otheNise appears to be materialty misstsled. If we hjenbfy such material inconsistencies or apparent material misststements, we are required to detennine whether this gtves rise to a matenal misstslement in the finan¢ial stalements Ihemselves. If, based on the work we have performed, we con¢lude that the￿ is a material misstatement of this other infom￿110n, we are required to report that fact We have n¢)thing to report in this regard. OPINION ON OTHER MATfERS PRESCRIBED BY THE COIAPANIES ACT 21)06 In our opinion, based on the work undertaken wi the course ofthe audit the infomiats'on grven in the Tntstees. Repjrt for the ￿anchal year for which the financial statements are prepared is consistent wth the ffinanaal ststements. the Tnjstees. Report ha5 been p￿pared in accordance wth applicable legal requirenknts. MAThERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION In the light of our knowledge and understanding of the charitable company and rts environment obtaingd in the course of the audit, VR have not idents'fied rnateri￿ mi55tatements in the Trustees, Report. We have nothing to report in respect of the following matters in relation to which co￿￿anieS Act 2006 requires us to report to you if, in our oynion.. adequate a¢￿untr"ng re¢ords have not been kepc or retums adequate for our audit have not been received from branches not visited by us", or the financial statements are not in agreement wth the ac¢xJunting records and retums; or ertain disclosures of Trustees. remunerab.on speetfied by law are not made," or we have not received all the inf0m￿tion and explanations we require for our audit, or the Trustees were not en￿'￿ed to prepare the financial statements in accordance wtth the small ¢ompanies regime and take advantage of the small companies. exempkn.ons in preparing the Truslees. Report and from the requirement to prepare a Strategic Repo Page 20 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarnnts•l INDEPENDENT AUDITORS. REPORT TO THE MEMBERS OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES ICONTINUEDI RESPONSIBILrriES OF TRUSTEES As explained more fulty in the Trustees. Respon$ibilrtie5 Statement the Tru$tee$ {who are also the directors of the charitsble ￿MpanY for the purposes of company lawl are responsibbe for the preparation of the financial statements and for bein9 sats"sfied that they give a true and fair wew, and for such internal control as the Trustees detemiine is necessary to enable the preparati￿ of finanaal stslements that a￿ free from material mis$tatewent. whether due to fraud or error. In preparing the financial ststements. the Trustees a￿ responsible for assessing the charilable companls ability lo continue as a going concem. disclosing, as applKable. matters related lo going concem and using the going concem basis of accounting unless the Tnjstees either intend to liquidate the charilable company or to cease operations. or have no realistic dtemative bLrt to do so. AUDITORS. RESPONS181LITIES FOR THE AUDIT OF TrIE FINANCIAL STATEMENTS Our objeclives a￿ to obtain reasonable assurance about whether the financial statements as a whole a￿ free from matenal misstatement. whether due to fraud or error, and to issue an Auditors, Report that indudes our opinion. Reasonable assurance is a hKJh level of assurance, bul is not a guarantee that an audit conducted in accordance with ISAS (UK) will thays delect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered matenal if. indNKlually or in the aggregate, they could reasonably be expected lo intluence the econcrfnic deaS￿n$ of users taken on the basis of these financial statements. Irregulari￿es. inthjding fraud. are instances of non-compliance wilh laws and regulations. We deS￿n procedures in line with our ￿SPOnSibl[l￿"e$, outlined above, to detect material Mlsstste￿￿nts in respect of irregularities, including fraud. The extent to whieh our Pr￿edU￿$ are capabbe of deteeling irregularities, induding fraud is delailed below: We obtained an understanding of the legal and regulatory frawoworks through our arLumulated knowledge an¢J ¢OrbWderat￿n of sector inf0m￿tr.0n that is applKable to the charitable company. We determined that the rnosl s￿nth¢ant whth are directly relevant lo spwfic assertions in the financial statements are those related to the financial reports.ng framework induding bul not limited to United lQngdom Generally Accepled Accounting Practice. the Charities Act 2011. Chanties SORP, the Companies Act 2006, Data Protection Act 2018 and tsx *iSlat￿n We obtained an understanding of the procedures and ¢c￿lT01S over the charitable company's operations and discussed these with those charged with governance. No matter5 of fraud were broughl to our attention during Ihat discussMIn. During our discussions with management. they assessed these as being the nonnal risks required to bo considered by us as audrtors by the Auditing Standards (such as management override and revenue recognition) but cOnfim￿O that no i￿egularitieS here occurred. This was confimed by our review of management meetings. audikn.ng management override through joumal testing, and other adjustments lo consKler appropriateness, review of the financial stslemenls to ensure no unusual and l or inexplicable variances and general discus$w)ns with Managen￿nt during Ihe course of the audrt. We did not identify any signrficant busines5 transactions outside the nomal ¢our5e of th business operations. Our senior 5tstutory auditor has assessed that the audrt team possessed the abilty and competence to identify and recognise non4ompliance wth the relevant law5 and regulat￿n$ ¢entral to the operation of this charitable company. We have not Klents"fied any addrtional laws and regulatsons which are central to the entity's operations and which we were not nobfied atthrt. during the coutse of our audit fieldwork. Page 21 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantee) INDEPENDENT AUDITORS. REPORT TO THE klEMBERS OF THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (CONTINUED USE OF OUR REPORT We believe that our audit was capable of detecting material irregularities. including fraud, and our audit procedures were designed to respond to risks of material rnisstalement in the financial slatemenls. recognising that the risk of not detecting a material misststemenl due lo fraud is hrgher than the risk of not dele¢ting one resulting from error, as fraud may invofve deliberate concealment by, for example, forgery, misrepresentstions or through collusion. The￿ are inherent limitations in the audtl procedures perf0rff￿d and the further removed non- compliance with laws and regulations is from the evenls and transactions rellected in the financial staterrents. the less likely we are to become aware of IL A further description of our responsth"liknes for the audit of Ihe ffinanual statements is k)cated on the Financial Reporting Council's website at. www.frc.o .ukJauditorsres nsibilities. This descriptr.on fonns part of our Auditors, Report. This report is made solety to the charitable ¢ompan¥s members, as a body, in a¢cordanee wtth Chapter 3 of Part 16 of the Companies Act 20C6. Our audit work has been undertaken so that we might state to the charitsble company's members those matters we are required lo state to them in an Auditors, Report and for no other purpose. To the fullest extent permitted by lam, we do not accept or assu￿￿ responsibility to anyone other than the charitable ¢ompany and rts members. as a body, for our audrt woth. for this report, or for the opinions we have fom)ed. Mark Murray Bcorri kcA for and on behalf of Hill Wooldridge & Co. Li 107 Hindes Road Harrow Middlesex HA11RU CCA (Senior Statutory Audltor) Date.. Page 22 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarante¢) STATEMENT OF FINANCIAL ACTNMES (INCORPORATING INcopaE AND EXPENDITURE ACCOUNTI FOR THE YEAR ENDED 31 DECEMBER 2023 Unrnstrieted fund5 2023 Total funds 2023 Total funds 2022 INCOME FROM: Donations Charitsble activibes Investments Other income 5.987 7.450.000 1.442.229 37.160 5,987 7.450.000 1.442.229 37.160 6,660 7.170,0(10 930,724 56,936 TOTAL INCOME 8.935.376 8.935,376 8,164,320 ExPEND￿VRE ON: Raising funds Charitable actI￿tieS 482.511 3.893.496 482.511 3.893.496 531.513 6.558.(VJ1 TOTAL EXPENDITURE 4.376.007 4.376.007 7.089,604 NET INCOME BEFORE NET GAINS ON INVESTMENTS 4,559.369 5.309.364 4.559.369 5.309.364 1,074.716 {10.964.7371 Net (lossllgain on investments NET MOVEMENT IN FUNDS 9,868.733 9.868.733 19,890.021) RECONCILIATION OF FUNDS: Total funds brought foTh¥ard Nel movement in fvnds 89,288,678 9,868,733 89,288,678 9,868,733 99,178,699 {9,890,021) TOTAL FUNDS CARRIED FORWARD 99,157,411 99,157.411 89,288,678 The Statement of Finanaal ktr"vitses includes all gains arKI losses recOgn￿ed in the year. The notes on pages 26 to 44 forrn part of these financ￿1 statement& Page 23 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Gu•rantso1 REGISTERED NUMBER: 08239097 BALANCE SHEET AS AT31 DECEMBER 2023 2023 2022 Note FIXED ASSETS Tangible assets Investments 12 13 49,391 89.S66,473 63.507 83.177,926 89.615.864 83,241.433 CURRENT ASSETS Debtors Cash at bank and in hand 14 4n.980 9.866,685 3S8,895 6,332,321 10.344.665 6.691.216 Creditors.. amounts falling due within one year 15 (803,118 {643.9711 NET CURRENT ASSETS 9,$41,547 6,047.245 TOTAL NET ASSETS 99.157,411 89,288,878 CHARITY FUNDS Unrestricted fvnds 16 99,157A11 89,288,678 TOTAL FUNDS 99.157,411 89.288,678 The Trustees acknowledge their reswnsib1l￿.es for complying with the requirements of the Act with respect to accountsng records and prepafation of financial ststements. The ffnan¢ial ststements have been prepared in a¢cordance with the provisions applicable to entitie$ subject to the small companies regime. The finanual ststements wefe approved and authorised for issue ty the Trustees and syned on their behalf by.. Profes8or F Michelangeli Trustee Date.. 0910912024 The notes on pages 26 10 44 fo￿ part of these financial stalernents. Page 24 ThE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarantee STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 DECEMBER 2023 2023 2022 Not• CASH FLOWS FROM OPERATING ACTMTIES Net cash from operating activths 18 3,171.318 307.105 CASH FLOWS FROM INVESTING ACTivmES Dividends, interests and rents from investff*nts Repayment of social investr*nt Proceeds from sale of investments Purchase of investments 1,442.229 930.724 72.129 90.779.408 31,539.222 191,858.5911 {33,646.9291 NET CASH PROVIDED BYI{USED IN) INVESTING ACmVttlES 363,046 11.104.854) CHANGE IN CASH AND CASH EQUIVALEKfs IN ThE YEAR 3.534,364 6,332,321 97.7491 7.130.070 Cash and cash equivalents at the beginning ofthe year CASH AND CASH EQUIVALENTS AT THE END OF THE YEAR 19 9.866,685 6,332,321 The notes on pages 26 to 44 form part of these financial statements Page 25 THE FEDERATION OF EUROPEAN BIOCHEIAICAL SOCIETIES IA Company Llmil•d by Guarant•fr NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ACCOUNTING POUCIES 1.1 BASIS OF PREPARATION OF FINANCIAL STATEMENTS The financial statements have been prepared in accordance vAth the Charities SORP IFRS 1021- Accounting and Reporb"ng by Charibes". Statement of Recommended Practice applicable to charities preparing their a¢¢ounts in a￿rdan￿ wrth the Finanoal Reporting Stsndard applicable in the UK and Republic of Irelan¢J IFRS 1021 leffeetive 1 January 2019), the Financial Reporting Stsndard applicable in the UK and Republic of Ireland {FRS 102) and the Chanlies Act 2011 and the Companies Act 2006. Assets and liabil￿eS are inits.alty recognised at histori¢al cost or transaction value unless otherwse ststed in the rdevant accounts.ng policy. The Federation of European Biothemical Soo'eties meets the deffinrlion of a public benefft entity as defined by FRS 102. There were no S￿nffiCant estr"mates or judgements made by management in preparing these financial slatenRnts. The functional and presentstional currency rs the Euro. 1.2 GOING CONCERN The Trustees have cnnsidered the Companls forecasts and projeclions. After making enquires. the Truslees have concluded thal there is a reasonable expectation that the Company has adequate resources to continue in opeTrts"onal e￿stenCe for the foreseeable future. Therefore. these accounts have been prepared on the png ¢oncem basis. The￿ are no material uncertainlies in relation to goirKJ concem. 1.3 INCOME AJI income is recognised once the Company has entitlement to the incorr*, it is probable that the income ￿11 be received and the amount of income recewabk Can be meaSU￿d reliably. Income from royath'es ts re¢oJnised in line with tre peMd to whth it ￿lates. Income from grants and donations are recognised when the Company has been notified in writing of both the amount and settlen*nt dale. In the event that a grant or donation is subject to conditions that require a level of performance before the Company is enb'tled to the ftjnds, the income is deferred and not rewnised until those condit￿n$ are fully met, or the fvlfillment of those conditions is whdly within the control of the Company and rt is probable that those Condit￿n$ will be fulfilled in the reporting period. Investment #i¢onE is recognised in ts period in which the Company becomes entitled to the in￿me. Interest on funds held on depogt is indLrfled when receNable and the amount can be measured reliably by the Company., this is nomalty upon notification of the interest paid or payable by the Ban Other in￿rne is recognised in the peri¢xI in whth it is receNable and to the exlent the goods have been provided or on ¢ornplets"on of the service. Page 26 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited ty Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 OECEMBER 2023 AccouKfiNG POUCIES (CONTINUED 1A EXPENDrruRE Expenditure is recognised once there is a legal or constructive oblvJation to transfer economic ben8fit to a third paty. it is probable that a transfer of economic benefits will be required in settlement and the amount of the obligation can be w*asured relh3bly. Expenditure on raising funds indude5 all expendrture incurred by the Cwrtpany to raise fund$ for its tharitable purposes and includes costs of all fund￿Sing activities events and non-charitsble trading. This comprise$ investment management fees. Expenditure on charitable acty.vrt￿s is incurred on directly undertakn'ng the activities which fvrther the Companls objecttves. a5 well as any associated support Costs. Allccation of Costs is based on athvty whith has driven Ihe relevant cost. Grants payable are charged in the year when the offer is made except in those cases where the offer is conditional, such grants being recognised as expendrture when the condib.ons attaching are fvlfilled. Grants offered subje¢t to conditions which have not been met al the year end are noted as a ommitrnent, but not ac(xued as expenditure. Governance Costs are those incurred in ct)nne¢tion ¥￿h administration of the Company and compliance with o)nstitutM)nal and slatuatory requirements. 1.5 FOREIGN CURRENCIES Monetary assets and liabikti'es denominated in foreign currencies a￿ translated into euros at rates of exchange rulin9 at the feporknng date. Transaclions in foreign currencies are translated into euros at the rate ruling on the date of the transaction. Ex¢honge gains and losses are recognised in the Statement of Finan¢ial Activities. 1.6 TAXATION The Company is ￿nSIdered to pass the tests set out in Paragraph 1 Schedule 6 of the Finance Act 2010 and therefore it meets the definilion of a charitable company for UK corporation tsx purposes. Accordingly, the Company is potentsally exempt from taxation in respect of income or ¢aprtal gains received within categories covered by Chapter 3 Part 11 of the Corporatron Tax Act 2010 or Section 256 of the Taxation of Chargeable Gains Act 1992. to the extent thal such incnme or gains are applied exdusivety to charitable purF4)ses. 1.7 TANGIBLE FIXED ASSETS AND DEPRECIATION Tangible fixed assets are initi.ally recognised at cost After recognition, under the cost model. tangible fixed assets are measured at cost less accumulaled deprecrats.on and any accumulated impairment losses. Al costs incurred to bring a tsngible fixed asset into its intended Working condition should be included in the measurement of cost Page 27 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantee NOTES TO TrIE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ACCOUNTING POLICIES {CONTINUED) 1.7 TANGIBLE FIXED ASSETS AND DEPRECIATION (COMTINUEDI Deprec￿110￿ is charged so as to alk¢ate the cost of tsngible fixed assets less their residual value over their ests'mated usefijl lives. Depreciab'on is provided on the folhjwing bases". Leasehold lmproveff￿nts Fixtures and frtts.ngs Computer equiprrent website - over the lrfe of the lease 15% on reduang balance 25% on reduang balance 1.8 INVESTMENTS Fixed asset investments a￿ a fo￿ of ffinanryal instrun*nt and a￿ inth'ally recognised at their transaction cost and subsequentty measured al frdir value al the Baknee Sheet date, unless the value cannot be measured Tel￿b￿ in which case il is measured al cost less impairment. Investment gains and losses, whether realised or unrealised. are combined and presented as 'Gainsl{Lossesl on investments, in the Statement of Financial ActI￿￿"e5. 1.9 DEBTORS Trade and other debtor5 are ￿Cognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount Pfepahl net of any trade discounts due. 1.10 CASH AT BANK AND IN HAND Cash at bank and in hand indudes cash and short-term h￿hty IKIUKI investments with a short maturity of three months or less from the date of acquisttion or opening of the dewsit or similar account. 1.11 LIABILMES AND PROVISIONS Liabilities are recognised when there is an obligalKJn at the Balance Sheet dale as a re$ull of a past evenl. it is probable that a transfer of economi¢ benefit will be required in settlement, and the amount of the 5ettlernÈnt can be estimated reliably. Liabilities are recognised at the amount that Company anticipates it wll pay to settle the debt or the amount rt has received as •Jvanced payments for the goods or seNKes it musl provide. Provisions are measured al the best estimate of the amounts required to settle the obligation. Where the effect of the lime value of money is malenal. the provision is based on the present value of those amounts, discounted at the pre-tax discount rate that rellects the risks specffic to the liability- The unwinding of the discount is recr)Jnised in the Slalement of Financial ActNrbes as a finance cost Page 28 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Cthnpany Limited ty Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ACCOUNTING POLICIES (CONTINUED) 1.12 FINANCIAL INSTRUMENTS The Company only has finanual assets and financial liabllrt￿S of a kind that qualify as basic financial instruments. Basic finanual instruffents are initially recogn￿ed at transaction value and subsequently measured at their ¥etue￿￿nI value wlh the excepth.on of bank loans which are subsequently measured at amortised ¢ost using the effe¢b"ve interest methtsj. 1.13 OPERATING LEASES Rentsls pa￿ under operatsng leases a￿ ¢harged to the Ststemenl of Financial Activities on a straight4ine basis over the lease temi. 1.14PENSIONS The Company operates a defined (￿ntr￿u￿On pension scheme and the pension tharge represents the amounts payable by the Corryany to the fund in respect of the year. 1.15 FUND AccoupmNG General funds are uThrestr￿ fvnds whth a￿ available for use * the dis¢retion of the Trustees in funherance of the general obieclives of the Company and which have not been designated for other purwses. CRrricAL ACCOUNTING ESTIMATES AND ARES OF JUDGEMENT Estimates and judgments are eontinually evaluated and are based on historical experience and other fxtors. The resulting accounting estimates and assumptions wll, by definition. seldom equal the related actual results. There are no ests"mates and assumpts.ons that have a 5ignTfieant risk of causing a material adjustment to the &irrwng amounts of assets and liabilities wthin the next financial year. INCOME FROM DONAnoNS Unr•stricted funds 2023 Total fund$ 2023 Subscriptions receivable 5,987 5.987 Unrestricted fvnds 2022 Total funds 2022 Subscripts'ons receNable 6,660 6,660 Page 29 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 INCO•AE FROM CHARITABLE ACTI￿nEs Unrestricled funds 2023 Total funds 2023 Royaliies recervable 7,450,OCKI 7,450,000 Unrestricted fvnds 2022 Total funds 2022 Royalties receNabie 7.170,f))O 7,170.000 INVESTMENT INCOME Unrestricted funds 2023 Total funds 2023 Franked investment in¢otYE- dividends Interest re¢eNed 836.584 605,645 836,584 605,645 TOTAL 2023 1.442,229 1A42329 Unrestricted funds 2022 Total fvnds 2022 Franked investment Ir￿lM8- diwdends Interest received 608.294 322.430 608,294 322,430 TOTAL 2022 930.724 930.724 Investment income from UK investment assets was E317.290 (2022.. É198.2441. Investment income from investment assets out&de the UK was E1.124,939 {2022: Q32,480). Page 30 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guardntee} NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 OTHER INCOMING RESOURCES Unr•stricted funds 2023 Total fund8 2023 Other income 37.160 37.160 Other incoming resources compnse redlarges on editorial actNibe$. un￿StrIded fund$ 2022 Total funds 2022 Other income 56.936 56.936 INVESTMENT MANAGEMENT COSTS Unrestricted funds 2023 Total funds 2023 Portfolio managemenl 482.511 482,511 J.P. Morgan Private Bank. the Compansls inves1Th￿nt manager, holds a charge over the Companl5 cash and investments rt manages on behaw of the Company. Unrestri¢led fund5 2022 Total funds 2022 Porttolio management 531,513 531,513 Page 31 THE FEDERATION OF EUROPEAN BIOCHElJllCAL SOCIEnES IA Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ANALYSIS OF EXPENDITURE BY ACTivmES Grant A¢tfvilie8 funding of Support and undertaken actlvltles governance direclty {note 91 costs 2023 2023 2023 Tolal funds 2023 Joumals Congress Fellowships Advanced courses Other 275.760 261.124 1.023,284 124,496 93,420 143,924 123,299 1,299.044 655.713 1,131,896 497,349 309N94 270,093 1.038,476 353,425 63,538 122.657 659,541 1.725,532 1,508,423 3,893,496 Grant funding of Support and actr"vities govemance Inole 9) costs 2022 2022 "vib"es undertaken direcdy 2022 Total funds 2022 Joumals 363.445 233.823 2.336.428 379.866 219.575 264.795 916,330 2,899.873 864,148 1,113.318 771.243 1,109.509 Congress Fellowships Advanced courses Other 250,459 893,743 506,448 86,858 106.321 703.589 1,737,508 4,116,994 6,558,091 Page 32 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ANALYSIS OF EXPENDITURE BY ACTMTIES {copillNUED} ANALYSIS OF DIRECT COSTS Total funds 2023 Joumals 2023 Congre88 2023 Other 2023 Editorial fees and expenses Women in science events 275.760 275,760 5,328 5,328 Educats'on. fellowship and advanced courses committee evenl$ S¢ien¢e and Soaety events National lecture expenses Expenses and publioty at other COnferen￿S World Wide lecture expenses FEBS Congress FEBS Young Scientists fowm congress WGI Participation events Spinzl sd*me 9,447 43.505 3.500 2.997 108 234 52,952 3,500 2.997 108 234 137.211 107.138 72.313 2,000 137.211 107.138 72.313 2.000 275.760 261.124 122.657 659,541 Total funds 2022 Joumals 2022 Congress 2022 Other 2022 Editorial fees and expenses Women in saence events 363,445 11,554 11.554 Education. fellowship and advanced course$ committee events Science and Scciety events Nats'onal le¢ture expenses FEBS Congress FEBS Young Scberbbsts fofum congress WGI Participalion events Spinzl stheme 7.562 38,841 4.868 5.505 46,403 4,868 5,505 79,465 130,202 57,107 5.040 79.465 130.202 57,107 5.040 363.445 233.823 106.321 703,S89 Page 33 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Llmlted ty Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ANALYSIS OF EXPENDITURE BY ACTMTIES (CONTINUED) ANALYSIS OF SUPPORT COSTS Advanced COu￿e8 2023 Journals 2023 Congress Fellowships 2023 2023 Editorial fees and expense5 HR and communi¢ab"on$ Finance and governance IT & Web￿te Education, fellowship and advanced courses committee events Foreign ex¢hange gains 1.142.643 42.314 127.423 1.894 65.588 116,79) 316 16,926 60,784 316 16,926 91,945 316 44,493 129,0991 63,836 (29,0991 (290.9901 158,198) 1,023.284 124,496 93,420 143,924 Tolal funds 2023 Other 2023 Edilofial fees and expenses HR ar¢d communi¢atsons Finance and governance IT & website Education, fellowship and advanced courses committee events ForeKJn exchange gains 1.142,643 211,574 621.541 6.316 108,329 1581,980) 69,820 224,599 3,474 1174.594} 123.299 1,S08,423 Page 34 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Comp•ny Llmlled by Guaranl¢e) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ANALYSIS OF EXPENDITURE BY ACTMTIES (CONTINUED> ANALYSIS OF SUPPORT COSTS (continued) Advan¢ed cnurses Joumals 2022 COng￿$S Fellwhips 2022 2022 2022 Editorial fees and expenses HR and communications Finance and govemance IT & website Edu¢atson, fellowship and adV￿Ce￿ courses rA)mmittee events Foreign exchange losses 1,123.287 7.948 90.286 6.246 61,600 90,286 6.248 7.948 34.395 6.248 13,910 77,388 6,248 60.118 110.866 $6,383 110,866 1.108.661 221.732 2.336.428 379.866 219,575 264.795 Total funds 2022 Other 2022 Editr)rial fees and expenses HR and communications 1,123.287 198.710 429,936 31.238 116.501 2,217,322 107,304 137.581 6,248 Finance and govemance IT & website Educats'on. fellowship and advan¢ed courses comTh¥ttee events Foreign exchange losses 665.197 916.330 4.116,994 Page 35 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Llmitod by Guar•nt••l NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 ANALYSIS OF GRANTS Grants to Grants to Institutions Individuals 2023 2023 Total funds 2023 Congress Fellowships Advanced ¢ourses Other 143.160 126.933 1.038,476 56,097 34,799 270,093 1.038.476 353A25 63,538 297.328 28.739 TOTAL 2023 469,227 1.256,305 1,725,532 Grants to Insb"tutyons 2022 Grants to Individuals Total funds 2022 2022 Congre$$ Fellowships Advanced courses 89,426 161,033 893,743 73,277 38.209 250,459 893,743 506,448 86,858 433,171 48.649 Other TOTAL 2022 571.246 1.166,262 1.737,508 The Company has made the fdl¢Ming material grants to institutions during year. 2023 2022 NAME OF INSTITUTION Advanced courses FEBS Congress Grant Grantslsponsorship to other organisalionslo)nferen FEBS3+ Grant Alian¢e for Biomedical Research Grant 297,328 143,160 433,171 89,426 3,290 40,359 5,000 12.129 16,610 469,227 571.246 Page 36 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 10. AUDITORS. REMUMERAIK>N 2023 2022 Fees payable to the Companys audilor for the audit ofthe Coffrf)anYs annual acc¥JJnts 21.338 20,650 11. STAFF COSTS, KEY PIANAGEMENT PERSONNEL AND TRUSTEES. REMUNERATION AND EXPENSES 2023 2022 Wages and salarie$ Social seeunty costs Other pension ¢osts 1,060,987 168,6S6 109,269 963.723 155,975 99,635 1.338,912 1.219,333 The average number of persons empk)yed by Corrrf)any dunn9 the year was as follows.. 2023 2022 Publications (Cambridge, UK) Publications (Heidelbery. Gem￿ny) PUbliCat￿S (Barcelona. Spain) Treasury ICambrid9e, UK) Central admin (Cambridge. UK) Central admin {Spain) 21 20 Page 37 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES IA Company Limited by Guarnntee} NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 One employee receNed Rmuneration falling with#) the band QO.000 to a9.999. The key management personnel of the Company comprises the Twstees. The Trustees all give their time and expertise without any kind of remuneration or other benefit in kind with the exception of the ft)Ilowing Trustees who provided services to the Company during the yew.. 2023 2022 De La Rosa {Editorial seryiosl l Diaz Moreno {Edrtorial servi￿) C Arraiano (Editorial services) vèrtessy (Editorial services) F Mithelangeli (Editorial Services) 32,216 400 25.266 585 200 360 120 160 33,096 26,211 These services are in accordance the CompanWs goV￿ning document and in accordance with sections 185 to 188 of the Charities Act 2011. During the year, 14 12022". 121 Trustees recewed reimbufsemenl of expenses or had expenses paid directly to a third paty on their behaw lotslling É66,68512022. E35.645). Oth•r personnel costs Due to the wide geographical spread of the Companls ath"vities. some staffing requirements are fulfilled by independent parties and freelancers. Detsils of the Mst and number of personnel contracted in this manner are detailed tdow 2023 2022 Fellowship CoMM￿ee Adminislrabon Advanced Courses Committee Admintstration 30,800 29,973 28.000 26.872 60,773 54.872 Page 38 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIEllES IA Company Lifflitod by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 The average number of other such personnel (induding part-b.me personnel) engaged by the Company dunng the period was as follows: 2023 2022 Fellowship Committee Administrator Advanced Courses Committee Administrator 12. TANGIBLE FIXED ASSETS Computer LeaselHAd Flxtures and equipment improvements ffttings and website Total COST Al 1 January 2023 Disposals 59.681 12.390 (5341 104.338 111,909 176.409 112,4431 At 31 December 2023 59,681 11.856 92,429 163.966 DEPRECIATION At 1 JanLbary 2023 Charge for the year On disposals 19,421 6304 5,427 1,045 13631 88.054 4.071 19.2841 112,902 11,320 (9,6471 At 31 DecemÈ*r 2023 25,625 6.109 82.841 114.575 NET BOOK VALUE At 31 December 2023 34,OS6 5,747 9.588 49,391 At 31 December 2022 40.260 16.284 63,507 Page 39 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limited by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 13. FIXED ASSET INVESTMENTS Llsted Cash held at Investments broker Total VALUATION At 1 January 2023 Additions Disposals Ipro¢ee(1s É90.779.408.' realised gain £3.270,305) RevalUat￿n$ Cash movement 82,$66,673 90,576,150 611,253 83,177,926 90,576,150 (87.509.103) 2,039.059 (87,509,103 2,039,059 1,282,441 1.282M1 AT 31 DECEMBER 2023 87,672,779 1,893,694 89,S66,473 The market value ol investrwil assets in the UK is É14.009.745 {2022: É10.282.693). The market value of inveslmenl assets Outts￿e the UK is V3.663.034 (2022: U2.283.980). FEBS seeks to produce the best financial retum wthin an acceptable level of risk. The investments are to enable FEBS to fund rts activrties in the long4em. The retums on investrnent a￿ to provide funding of ¢harilable aclivits'es and to increase the size of the investry￿nt fund in the next 7- 8 years. The aim is to increase the size of the investsnent fund to provide.higher incnme in the future to offset any potential reduction in income from royalt￿5. The inveS￿nt objective is to generate a relum of HICP plus 3.5%, over the long temi, after expenses. HICP the Harff￿nised Index of Consumer Prices is to be used as a measure. This Shou￿ albjw FEBS to at least maintain Ihe real value of the assets. whilst funding annual expenditure over time. FE8S has a target kvel of investrnent that will cover any shortfall from publi¢ations income. FEBS uses a totsl ￿tUffl investment strategy. The total net gains on invest￿nts as per the Statement of Financial Activities comprises iealised gains ofÉ3,270,305 and unrealised 9ains of Q.039,059. 14. DEBTORS 2023 2022 Trade debloTS 64.674 77,561 335,74S 146.393 62.154 150,348 Other debtors Prepayments and a¢¢rued in¢cffie 477.980 358.895 Page 40 THE FEDERATION OF EUROPEAN BIOCHE1411CAL SOCIETIES (A Company Limited by Guarnntso) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 310ECEMBER 2023 13. CREDITORS: AMOUNTS FALLING DUE wrrHIN ONE YEAR 2023 2022 Trade ¢redrtors Other taxabon and social security Other creditors A¢cruals and deferred incoff 674.543 16.192 212,873 349,499 2,704 78.895 104,338 803,118 643,971 16. STATEMENT OF FUNDS STATEMENT OF FUNDS - CURRENT YEAR B•l•n¢• at 31 Gainsl December (LO￿¢$) 2023 Balance at I January 2023 Income Exyndithr• UNRESTRICTED FUNDS General Funds 89,288,678 8,93S,376 14,376,0071 S￿09,364 99,157M11 STATEMENT OF FUNDS- PRIOR YEAR Balance at 31 December 2022 Balance at 1 January 2022 Gainsl (Losses) Income Expenditure UNRESTRICTED FUNDS General Funds 99.178.699 8,164,320 {7.089.6041 (10.964,737) 89,288,678 Page 41 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES {A Company Llmlted by Guarantee) NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 17. ANALYSIS OF NET ASSETS BETWEEN FUNDS ANALYSIS OF NET ASSETS BETWEEN FUNDS- CURRENT YEAR Unrestricted funds 2023 Total funds 2023 Tangible fixed assets Fixed asset investments Current assets Creditors due within one year 49,391 49.391 89.566,473 89,566.473 10,344.665 10,344,665 1803.1181 (803,118 TOTAL 99. 157,411 99.157.411 ANALYSIS OF NET ASSETS BETWEEN FUNDS - PRIOR YEAR Unrestricted fvnds 2022 Total lunds 2022 Tangible fixed assets Fixed asset investments Current assets 63,507 63,507 83.177.926 83.177,926 6.691.216 6,691,216 {643.9711 {643,9711 Creditots due wtthin one year TOTAL 89.288.678 89.288.678 Page 42 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETES IA Company Limited by Gu•rants• NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 RECONCILIATION OF NET MOVEMENT IN FUNDS TO NET CASH FLOW FROM OPERATING ACTIVITIES 2023 2022 Net in¢om81(expenditurel for the year {as per Ststement of Fin•cial Activrties) .868.733 {9.890,021) ADJUSTMENTS FOR: Depreciation charges (Gainslllosses on investments DNidends, interests and rents from investments Loss on the sale of fixed assets Ilncreaseydecrease in debtors Increase in crediiors 11.320 12.861 15.309.364) 10.964,737 11,442.2291 1930.724} 2.796 (119.0851 159.147 77,757 72,495 NET CASH PROVIDED BY OPERAnNG ACTivmES 3,171.318 307.105 19. ANALYSIS OF CASH AND CASH EQUIVALENTS 2023 2022 Cash in hand 9,866,685 6.332.321 TOTAL CASH AND CASH EQUIVALENTS 9,866,685 6.332,321 20. ANALYSIS OF CHANGES IN NET DEBT At1 January 2023 Cash flows At31 D•cember 2023 Cash at bank and in hand 6,332.321 3,534,364 9.866.685 6.332.321 3,534.364 9.866.685 Page 43 THE FEDERATION OF EUROPEAN BIOCHEMICAL SOCIETIES (A Company Limit•d by Gu•rantee) NOTES TO ThE FINANCIAL STATEMENTS FOR THE YEAR ENDED 31 DECEMBER 2023 21. OPERATING LEASE COIAMrrMENTS At 31 December 2023 the Company had commtlments to make luture minimum lease payments under non-cancellable operatiThJ ￿Se$ as follows.. 2023 2022 Not later than 1 year Later than 1 year and not later tt￿n S years 14.280 55.969 13.992 14,280 69.961 RELATED PARTY TRANSACTIONS The Company has not entered into any related paty transaction during the year, nor a￿ there any outstanding balances owng between related parties and the Company at 31 December 2023. Page 44 The Nerherlands Society for 81￿hemistry and Molecular Biology INVBMBI. Bijyoet Centèr for Biomolecular Research. Utrecht UnNersity, 3584 CH Utiecht. The Netherl3nds www.kncv.nl Trvbmb Norwegian Biosciente kKiety INBSI. NTNU Dept. of Clinical and Molecular Medicine, PO 8ox 89 Trondheim 7491. Norway www.biok"emi5k.com Polish Biochemical Society (PT Biochl. M. Nencki Institute of Experimental Biology. PO Box 38, Pasteur str. 3. 02-093 Warsaw Poland www. tbioch.edu. Portuguese 8icrhemistry S￿iety ISP81. School of Medicine and 8iornedical Sciences IIC8AS1, University of Porto, 4099-￿2 Porto. PortU8al www.s Romanian Society of 8iochemi5try and Molecular Bio108y IRSBMBI. Institute of Biochemisiry. Splaiul Independentei 296. 06CK318ucharesr. Romania www.srbbm.bicKhim.ro National Committee ol Biochemists and Moleculai Biolog5Sts INCBMBI Shemyakin-ovchinnikov Institute of 8icioiganic Chemistry. RAS. 117997 Moscow. Russia www.rusbiochem.or Serbian Biochemical Sc(iety158S1, Faculty of Chemistry. University of 8el8rade. Studentski trg 16. 11000 Belgrade Serbia htt www.bds.or home. Slovak Sotiety for Biochemistry and Molecular 8iology ISSBMBI. Faculty of Science, Charles University in Bratislava, Ilkowtova 6. 842 15 Bratislava Slovak Republic www.55bmb.sk Slovenian Biochemical Society ISBDI. Jozek Stefan Institute, Jamova 39, SI-ICKK) Ljubljana Slovenia www sbd.51 Sociedad Espahola de Bioquimica v Biologica Moleculaf ISEBBMI. c18￿1C. clRamiro de Maetzu, 9 E-28040 Madrid. Spain www.sebbm.es The Swedish Society for 8iocherni5try. Biophysics and Molecular Biology ISFBBMI. Svenska Kemisamfund8t, Storgatan 19 4 tr. 114 $1 St(Kkholm, Sweden htt kemisèmfundet.se 5ektioner biokemi-b+o Ik-och-molek larbiol fe Science5 Switzerland ILS21. Molecular and Cellular Biosciences IMCBI section. University of Zurich, Department of Molecular Life Sciences. Winterthurer5trasse 190, Switzerland www.ls2.ch The Tunisian A5S0Ciation of Biological Sciènce5 IATSBI ATSB. Dep Biologie - INSAT, BP 676- Centre Urbatn Nord, 1080 Tunis, Tunisie www.aisb-bio.or Turkish Biochemical Society ITBSI. Hirfanli Sokak 913, 067(X) Gaziosmanpa¥a, Ankara. Turkiye www tvrkbi okim 3derne i.or Ukrainian Biochemical 5ociery IUBSI. Palladin Institute of Biochemistry, National Academy of Sciences, 9 Leonto¥icha St, Kyiv 01054 Ukraine htt www.biochemist .or .ua index. Biochemical Society. l Naoroji SL London. WCIX OG8. UK www. Netherlar Norway Pdand Portwl Romania Ru5Ia- SIoiAkta ovenla Spaln Sweden Swiizerland Tun151a (Associotej Tuthye Ukyalne Unltqd Kjn dom FEB5 had 39 Constituent Societ*s in 2023. comprising 35 Member Societies and 4 Associate Membèr Societiès. Constituent Society Armenja A550Clation of Armenian Biochemi515 IAABI H. Bvniatin1nst. of 8K)chemistry. NatK)nal Academy of Sciences. Yerevan 375014 Republic of Armenia www.3ab.sci.am Austria OGM8T. Vienna Biocenter, 1030 Wièn Austria www.oe mbt.at Belarus- IA5SOCiUtel The Bèlarusian Society of Biochemists and Moleculai Biologists18SBM81. Instit*Jte of Biochernistry. Natsonal AcadÈmy of scien￿5, 23(K)30 Grodno, Belai'us Be1￿uM Belgian Society for Biochemistry and Molecular Biology. Nanobody Lab. Dept. of Biochemistrv, Ghent University. 8-9(KK) Ghent Belgium www.biiKhemist .be Bosnla v Herze6o￿na Assctiation ol Biochemists and Molecular Biologists in 8osnia & Herzegovina IUBIA8UBIHI Faculty of Medicine. University of Sarajevo 71WO Sarajevo B05nia & Herzegovina www.ubtnbubih.net 8utgarla Bulgarian 8iochemical. Biophysical and Molecular 8iology Sooety18BM8SI. Institute of Biophysics. 8ulgarian Academy of Sciences. Sofia 1113. 8ulgaria www.old.usb-b .or sections.htm Croatio Croatian Society of 8iothemi5try and Molecular Biology IHDBMBI, Ksaverska cesta 2. IOLX)O Za reb Croatia www.hdbmb.hr Oioq-sooety ol Biological Sc5ences in Cyprus IF￿(-S85CvI. Department of Biological Science5, Unwersity of Cyprus, Aglandjia 2109. Nic05ia, Cypru5 htt sbsc .Of Czech Society lor Biochemisrry and Molecvlar 810108v ItSBMBI, Kladenska 48. CZ-16 000 Prague 6 ech Republic www.csbmb cz Danish S(Kiety for Biochemistry and Molecvlar Biology IDS8MBI, Bitstech Research and Innovation Centre18RICI. UnNersity of Copenhagen. Copenhagen, Denmark hrt www biokerni.eu Estonian Biochemical Society IEBSI. Akadeemia tee 15 - 228. 12618 Tallinn. Estoni C2ech Republk Denmork Estonla emi Societss Biochimica, 8iophysica et Microbiologica Fenniae18iobio Society). University of Helsinki. Haartmaninkatu 8, 002￿ Helsinki Finland www.biobio.or Société Francaise de 8iochimie et 8iolo8ie hAoléculaire1SF88MI. SF88M-Centre Univer5itaire, 45 rue des Saints-Peres. ?5720 Paris Cedex 06. France www.sfbbm.fr S￿latIon of Georgian 8iochemists IAG81, Institute of Chemical Biology. Ilia State University, 315 K.Cholokashvili Av.. Tbilisi 0162. Geor Gesellschaft fur Biochemie und M(Aekularbiolo8ie GBM e.V. IGBMI, Morfdder Landstr. 125 D-60598 Frankfurt/hAain. Germany www. bm-online.de Hellenic Sc£iety of Biochernistry and Molecular IHSBM8111 SO￿li0U St￿et. 11257 Athens Greece www.eebmb. Hungarian Biochemical kniety IMa8yar Bitskémiai Egye5ulet- MBKEI. Institute of Enzymology. Hungarian Academy of Sciences. H-1117 Budapesr. Hungary www.tTFbke Israel Society for Biochemistry and Molecular 8iolcey IISBM81, Weizmann Institute of Science. 234 Herzl St, Rehovot 761CWI. Israel www.weiimann.ac.il .ee Flnland Fran Georgla Gemianv Greece Hun8 Israel Societè Italiana di 8iochimica e 8io108ia Molecolare IS181. Fondazione Alessandro Volta. Villa del Grumello. Via per Cernobbio 11, 221￿ Corno. Ita￿ htt 5ib-biochemist Latvian 8iochemical Society ILaBSI. Latvian 8iomedical Research and Study Cenire. Ratsupites Street l. LV 1067 Riga. Latvia htt www.biochemicalsocie index.html Lithuanian BiochemKal Society ILBDI, Sauletekio al. 7. LT-10223 Vilnius. Lithuania www.biochemist Lattha UtP4Janla Moidow4 {Associute) Moldovan Society of Biochemistry and Molecular Bid08y IMSBMBI, Institute of Genetics. Physiology and Protection of Plants. Academy of kieTh￿s of Moldova, Chisinau, Moldova Moroccan Society of Biochemistry and Molecvlar Biology1SM8BMI, Hassan 11 University of Casablanca. Laborato of Sciences. Facul ol Sciences and Technique5. Mohammedia. Morocco A5SOCltste •Krntiers¢￿itt￿ 31 2CII3-".:- ThE Armeniail 120 strian A￿S￿l3t￿￿OI&th(vIar ￿le￿ence5c￿￿&r 750 187.50 été Eel8ede ￿<<￿￿*etde Witmrlttu I￿.cO ABMBW) Bc£ni4 ar￿ ￿11*1￿¥1￿4a Ir¥) eul8arf¥*SocietylDr 8¥K￿￿sty7. ￿￿￿Y¢S￿r￿ BK**y IL¥) 651 15?.7$ hsctietylu &￿￿￿•St￿arrtj BKlrcrfCSBM8 97.50 rwnish&xieEY *hEM￿try￿[￿j We£￿&T io Esta*an 8￿￿m￿al Ee51iÈdeemra Setts li 499 123.75 Iz Francaistde mtetde iirK) 27&0) 13 24.50 Ge5e115cTr*li ftir M¢dekvL¥bcltyYe.V.GW 2870 717.80 15 16 tyj 17 iozs 18 Ital￿nSL￿letyQI ￿e¢v1*￿4¥ 19 77 19.25 20 265 E62S 21 NpderfarAlse VEreThilr¢wryeither*enW¢y￿￿E IC67 266.75 22 75(0 23 Bittheffl￿1I Society 267.LYJ PortU8vÈse ￿0£h&M￿alsr£￿ty Sooethita Acfftar4de Bl2$ 26 27 c*4k so¢*iyforeixhfrTr*￿lr￿ ktrJe¢¥larfJc*yWB 55.rij ?*L¢tr¢M￿ll >x*tySBD 220 2711 677.75 Sknedishgx*ty 426 ILKSO 31 leSc*rtts S￿l￿t￿l￿ LS2 947 23&75 32 Tvrk ctrrtli 19)ts) 33 4425 1,10&25 Ukrairdan 17D.CIJ Tol¥A 23822 S.95S.50 Asry￿TE MEMeER5 -... ￿￿•11¥nSC¢1ety0I &KtremiStryard INfW8) rc¢¢aThSwetyolPr¢*•Ta5try￿ ￿e¥J￿81￿¥¥IWe￿8 Asswati￿oI ￿L¥￿alk*￿E5 (AT5B) COMPOSITION OFTHE FEBS COMMITfEESANDWORKING GROUPS AND THE GEOGRAPHICAL DISTRIBUTION OF THE MEMBERS January 1. 2023- December 31. 2023 term ends I p05itK)n for Ire-lelection to start 1.1.2024 EXECUTIVE COMMIThEE C￿ft1ry Elected in Starting Ending Jankg Kos ChairyErson Vice£hair Slovenia Li5bon120221 010123 3112 23. online120201 010121 311222 Gra¢aSoveral Vicelh3ir Pi)rtUBal Lsbon120221 010123 3112 23, Miguel A. Oe la Rosa Secretary General Congress Counsemor Spain online120211 010123 311225 O￿lne12020I Jerusalem12017) Pars120141 online120201 Jerusalem1201 Munich120161 L￿b00{2022} 010121 010118 010115 010121 OIOlJ8 090916 311222 311220 311217 Frank Michelangeli TreasU￿r ACttn8TreaSU￿r Piotr Laidler Con8ress Counsellor Chair Vicelhair Beata Vertessy Chair.Advanced Course5 Committee United K￿ed 3112 23. 311220 311217 Pdand 010123 311225 Krakow120191 010121 010120 010121 010118 010115 0808 311222 311220 31 12.23. 311220 311217 311214 Hurbgary o￿lne12020j Jeru5alem12017) Pans120141 Si PeteisbJr8120131 L￿bon12022l Krakow120191 Munich120161 online120201 Actingchair Alain Krd Chair, Fellowships"Committee FrnrKe 010123 010120 010117 010121 311225 311222 311219 3112 23. Johènnes Buchner Chair. Pu￿1(atIonS Ccxnmittee Germany Emrn3nouiI Fragkoulis Ch?iT. Science & 5DciEty Committee Gree L$bon120221 Krakow120191 Munich120161 online120211 Prague120181 010123 010120 010117 010122 311225 311222 311219 311224 Ferhan Sa8in Chair, Education Cornmittee Turkev 010119 311221 Darne C3roline Lkan Chair. Women in Science Working Group IWISEI Jerka DJmic cha￿r. Working Group on Integration IWGII United Ki￿( Lisbon120221 010123 311225 Croatia Is￿nI?022) Krakow120191 Munich120161 online120201 Jeru5alem12017) 010123 010120 010117 010121 010118 311225 311222 311219 3112 23, 311220 I￿ne DIa2-mo￿￿j Chair, WorkinBGroup onthe Careefs of Young Scient15ts Xavier Coum{￿1 Chair. Network Wgrking Group spain Frarte onlire120211 010122 311224 Israel Pecht Honororymember(non-voring. non- Director. non-frustee role) seC￿tary General jerus3￿MI2017} 010118 sew1￿(2012) Pra8ue12(X)91 Istèni￿1I2c￿￿l 010114 oioiii 010108 311216 311213 311210 4) ADVANCED COURSES COMMITfEE Beat3 Vertessy. Chair Hungary online120201 jeruSa￿rnI20I7) Pars120141 St Petersbur8120131 online120201 010121 010118 oioi 080813 3112.23 311220 311217 311214 ActinBChair Mutay AsLin TurkLry 010121 311224 Mateja Mancek Keber Sbverma Li%bon120221 010123 311226 Mauro Maccarone Ira Krakow120191 010120 3112 23° Kristiina Makinen Finla￿[ Krakow120191 010120 3112 23. Milagros Medina Spain Lsbon120221 010123 311226 Jan Riemer Germanv L¢sbon120221 .0101 23 311226 Frank Michelangeli {EX-Offic￿) T￿asurer ActingTreasurer Miguel de la Rosa (Ex-offiaoj Secretary General united Km8dom online120201 JenJsalem12017) Munich120161 online120211 010121 oioi 090916 3112 23° 311220 311217 Spain 010123 311225 EDUCATION COMMITfEE FerhanSa8in Chair, Educationcommittee Commiltee member Turkey online120211 Prague120181 Berlin120151 010122 010119 010116 311224 311221 311218 Manuel Joao Cost3 Portugal online120201 010121 311224 Francesco Malatesta Lsbon120221 010123 311226 Erkki Raulo Finknd Krakow120191 010120 3112 23. Nino Sinti Croatia L￿bOn(2022j 010123 311226 Ly Villo Estonia L￿bon12022j 010123 311226 Luciane Vietra de Mel United Kir£dom Ctropted 010123 311225 Winnie Eskild IC(Fopted. nort-votingl Ctropted 010121 Unlimlted Angel Herraez (Co-opted. ￿￿-¥01[￿9} Spain Berlin120151- Ctropted 010116 Unlimited Keith Elliott Ico-opted, non-¥Y)tingl United Kingdom C04)pted Unlimited Frank MKheiin8eli (Ex-(¥fiC￿j T￿asUrer Acting Treasurer Llnited Kw￿d0M online120201 Jefusalem120171 Mvnich120161 010121 010118 090916 3112 23. 311220 311217 Miguel de la Rosa IEx-OfficioJ Secretary General Spain online120211 010123 311225 Beata Vertessychair. Advanceij Courses IEx-offstioJ Hun8ary online120201 JenJsalem1201 Part5120141 St PeterslxJrg120131 010121 010118 010115 080813 3112.23" 311220 311217 311214 Actin8Chair. ACC Jerka Oumié {Ex-officioJ Chair, WorkingGroup on IntegratM)n Croatia Ltsbon120221 Krakow120191 Munich120161 010123 010120 010117 311225 311222 311219 FELLOWSHIPS cOMMI￿EE Alain Krol. Chair France L￿bon[2022j Krakow120191 Munich120161 ofiline120201 010123 010120 010117 010121 311225 311222 311219 311224 Tihomir Ba108 Croaba Valeriy FIl￿nk0 Ukraine online120201 010121 311224 marie-The￿S Hauser Austria Krakow120191 010120 3112 23. Ju551 Hepojoki F￿land online120211 010122 311225 Sebastian Hiller Germany online120201 010121 311224 Jolanièjura (Co-opted) Pdar Kfakow120191 Pr3gue120181 010120 010119 31 12 23. 311219 Macsej lakiwski FinLaThJ Krakow120191 01012C> 3112 23. Ari5tidis Moustakas G￿te Lisbon120221 010123 311226 Marek Mraz Czech RewblK Krakow120191 010120 3112 23. Natasa Ptsklar Ulrih SkNenia Lsbon120221 010123 311226 Ne5rin Kartal Ozer Turkey on14ne120201 010121 311224 Vicente Rulio Spain Krakow120191 010120 3112 23. Ayferyalcin Turkty 010122 311223 Jerusalem120171 010118 311221 Frank Michelangeli {Ex-offic￿} Treasurer ActiThgTreasurer United KJn8dom online120201 Jerusalem1201n Munich120J61 010121 010118 090916 3112 23. 311220 311217 Miguel de la Rosa {Ex4¥fic￿l Secretary General Spain jne120211 010123 311225 FINANCE COmMI￿EE Frank Mrhelangeli, Chatr T￿aSurer Act1ngTreasu￿r United Kingdom online120201 JerusaJem120171 Munich120161 010121 010118 090916 3112 23. 311220 3112 17. Francesco 8onc4ni It3 online120201 010121 311224 Joel 5ussm3n Israel Krakow120191 010120 3112 23. Laszkl Fésus Hun8ary 010121 3112 23. Miguel de la Rosa (£¥Qffic￿l Secretary General Spain onlinel20211 010123 311225 Johanne5 Buchner IEx-Offi¢tol Chaii, PublicatK*ns Cornmirree Gem￿n¥ o￿tne12020j 010121 3112 23. PU8LICATIONSCOMMirrEE Johannes Buchner, Chair Germanv o￿l￿e[20201 010121 3112 23. Marc Baurnann Fin￿nd online120201 010121 311224 Isabel Fabre Spain li5bon120221 010123 311226 Johannes Hefrrnann Germany online120211 010122 311225 Marcin Majka Poknd online120211 010122 311225 Rina Rosenzweig Israel. Lsbgn120221 010123 311226 Frank Michelangeli (Ex-offic￿l T￿aSurer ActingTreasurer Mguel de la Rw (Ex-offic￿l Secretary Ge￿ra1 United Kingdom online120201 jerus3￿MI2017) Munich120161 010121 010118 090916 3112 23. 311220 311217 Spain online120211 010123 311225 SCIENCE AND SOCIETY COMMFrrEE Emrnanouil FragkOUl￿. Chair G￿ece Lsbon120221 Kra*ow12019 Munich120161 online120201 010123 010120 010117 010121 311225 311222 311219 311224 Mauro Torti Ita Melifa Vidakow SerbKI online 120211 010122 311225 Enrique Viguera Minguez Spain online120201 010121 311224 Frank MKhelan8eli IEx-OfficK)J T￿aSUrer Actin8Treasurer United KI￿Orn online120201 JenJ$a￿Ml2OI?l Munich120161 010121 010118 090916 3112 23. 311220 311217 Miguel de la Rosa fEx-OffiooJ Secietary Ge￿131 Piotr Laidler fEx-OfficioJ Congres5 Counsellor Spain online120211 010123 311225 Pohrxj Lsbon120221 010123 311225 CAREERS OFYOUNG SCIEwnsrs COMMI￿EE Irene Dia2-Moreno, Chair Spain online120201 jerusa￿mI2017) 010121 oioi 311223 311220 Anna laguskik PoLiThJ Lsbon120221 c(￿pted Li5bon120221 C¢>opted Ctropted 010123 010621 010123 010621 311226 311222 3J1226 311222 Vlastimil Kulda Czech Repu￿ Marta Reyes Corral (Co-opted) Spain 010123 311223 Jerka Dumic (Co-optedl Croatia C(wted 010122 3112 23. Alexanijer Rontgen UK Co-opted 010923 311224 Sonia Trojan Poland CO￿pted 010923 311224 Frank M￿he1angeII (Ex-officol T￿aSurer ACtin8TreaSu￿r United Kingdc o￿lne12020j Jerusalem12017) Mvnich120161 010121 010118 090916 3112 23. 311220 311217 Miguel de13 Ros3 {Ex-OffK￿J SecietaryGeneral Spain online120211 010123 311225 i. INTEGRATION COMMIThEE Jerka fxjmit, Chair Cfoatia Ltsbon120221 Krakow120191 Munich120161 Lsbon120221 010123 010120 010117 010123 311225 311222 311219 311226 Natalija Polo4 Serbk4 Rasa 2ukienè thuani Lisbon120221 010123 311226 Frank Michelangeli lEx-Offit￿j Treasurer ActingTre3svrer Miguel de la Rosa (Ex-offic￿} Secretary General Ferhan Sa8in IEx-OffJooJ Chair, Education Cornmittee United Kingdom online120201 jenJsa￿m12O17) Munich120161 010121 oioi 090916 3112 23, 311220 311217 Spain online120211 010123 311225 Turkey online120211 Prague120181 010122 010119 311224 311221 Beata Vertessy fEx-OffK￿J Chair. Advanced Courses Comrnittee Hun83ry online120201 jeruSa￿MI2017l Paris120141 St Petersburg120131 010121 010118 oioiis 080813 3112.23. 311220 311217 311214 Acting Chair, ACC FE85 NETWORK COMMIThEE Xavier Cournoul, Chairperson Frnnte online120211 010122 311224 Andrea 6ellelli It3 Co-OPted120221 Pra8ve120181 nline120211 010123 OIOJ19 31 12 23. 311222 311225 Ali Burak Ozkaya Turkey 010122 La511ci Nyitray (Deleggtedl lex-FellowshipsCornrnitteel Enriqueviguera Minguez (Delegoted) Iscience and Society Committee) BorisTurk (Delegoted) lex-Publications Comfflitteel Hungary Dele8aied 010122 311225 Spain Dekgated 010122 311225 Sl¢Jvenia De￿gated 010118 31122S Irene Dia2-Mrxeno (Co-opredl Chair. Working Group on the Careeis of Youn8 Scientists Beata Vertessy Ico-optedl Chair. Advanced Courses CoMM￿ee Spain online120201 010121 3112 23, Je1usa￿Ml2OI7) 0101 18 311220 Hun8ary online120201 Jerusalem120171 Paris120141 St Petersbvr8120131 01 LII 2L oioi oioi 080813 3112.23" 311220 311217 311214 Actingchair. ACC WORKING GROUP ON WOMEN IN SCIENCE IWISEI Dame Caroline Dean Chair, Wtsmenin Science Workir Group IWISEI Frank Michelangeli 1Ex-Offit￿j Treasurer ActingTreasurer United KI￿dr￿n Li5bon120221 010123 311225 United Krngdom online120201 jerUsa￿MI2017) Munich120161 010121 oioi 090916 3112 23. 311220 311217 m￿Ue1 de la R05a lEr-L¥fic￿l Secfetary General Spain online120211 010123 311225 4penth* 4- Fellowships athd FEBS EX¢d￿nI Awards Long-Temi Fellowship$ 2023 ShortTerni Fellowships 2023 Fr•n Cork. wetsnd Alicante- Illa-Spa¢n Tampere. ￿lIk￿nd Lleidè. Rome. ltsty L*>n, UK From France Qe¢h RÈ ￿bI NetherLind5 To Nethwlands GÈtrnan Start Oare Oim¥2021 0110812021 1711012020 End date 3110SI2023 3V0712023 I6101n￿3 C6tth>ba. m￿nICh. Germarw sriasbour& Fran LOndoTr, UK Solna. 5wedEn HeidelbEr&Germwy Pari5. FrarKe Mont Ilier. Franci4 rTrws. D2nmark V￿￿Tha. Atrstri Aèrhu5, Denmatk fjermany vesteL tsech Republic FÉA FE85 EKellence Award5 Mobility Fhstory Year awarded Host(0￿￿[1¥ USA Netherland5 GÈtrnarry UK Beliium Belgium Austri 2021 2021 x)zi 2021 2021 2021 2021 2021 ha bDa. Portv8al 8ra8a. Powtu Lts￿￿n. Portu L¢idEn, Thp Nett*rtsnd5 Va*Trcia. Spain Infysbiuik. Au5tr& eged. Granada. Spain Wienna.Austrva tk)r05147.SanSebastilo.S Krakow. Poland TotinD. Ita Pts2na￿. Pol•Trd Patr￿.Greece Wrwknw. Polwd io an li 12 13 USA USA Gtrmatyl USA USA NeI￿rIa￿d5 Portuyl FfarK¢ 14 Is Au5trki POr￿gaI Germany Italy 2022 )22 2022 2022 2022 2022 2023 2022 2021 )22 16 Oxford. UK Ghent. Bel Pars. France Versailles. France Gipuikoa. Spain L￿D3, Portu Padr>v•. ltsl ZurKh. sw￿ertand OresdeD. Germany io USA Caftada l UK USA 17 iUrn li Ig 20 13 14 15 USA 8elwum Austri Germary 21 22 USAI UV ISr*l USA Is 17 23 USA 24 18 USA Gttmany Summer Fellowships 2023 Frix Zagreb. Croats M4dr*l. S Ankaia. lurke Porto. Portu Monia. Italy Poitts. Pryt lubmken. Gerrna thpn. Gerrnan Leeds. west Yoikshwt Oxlord. UX Jena, fjerm•n Gondomar Lyon, Fiawe Leiden. ￿ether￿Thd5 Am5terdarn. The Netherland5 uirechi. Nederland mbrid VK Diesden. GErm MDntpellier. FrarKe ok n. Poland Vienna.Au5tria Grai. Austria io li Ukrainian Short-Term Fellowshlp ZatpJk*tnD . Ukraine , Ukraine L￿. U&r￿nE Warsaw. PoL)nd Madnd. Spain FE85 Collaborattve Oevelopmentsl Scholarshlps Ft4M AhKa yiv. Ukio Lan . Gerrna London. UK Ap￿di￿S.FÉ8$Ady3Tr[￿d C(wrse5 202a NJM 26Febw3MITZIIS 4th¢5pa 12Mtyiais 221Atyto15M*fi23 2J￿raJo1un￿￿j PAYP202a Cr¢55t•lkbrtw¢•ittr*ECM JfttoUknJJ13 Jul￿5￿￿3}?> ISEpto8SopX12 Inv¢**atins rn•t*01￿ 45¢pt0ÈW￿2Y 25SeptpZ95va)25 3fyttD60tt202> OL7tg13(kt3111 w*r4 c￿￿￿rst￿￿￿d *JHBOSfLAnC*4 6PtytoJl I4u¥XQ> 102